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ABSTRACT
Alcohol use disorder (AUD) is a debilitating psychiatric illness that develops from a
combination of genetic and environmental factors. While it is well documented that AUD is
heritable, the shift from recreational alcohol use to abuse/dependence is poorly understood. In this
dissertation, using postmortem brain tissue from individuals with alcohol dependence (AD), we
profiled the genome-wide expression of circular RNA (circRNA), microRNA (miRNA), and
messenger RNA (mRNA) to better understand the impact of gene expression on the development
of AUD. To achieve this, we performed two independent studies that explore transcriptome
differences between AD cases and controls. The first of which examines differentially expressed
gene (DEG) networks associated with AD that show either high or low levels of network
preservation between two key areas of the mesocorticolimbic system (MCL), the prefrontal cortex
(PFC) and nucleus accumbens (NAc). The second is a pilot study that interrogates the function of
circRNA as miRNA sponges to impact the expression of mRNA. Overall, our findings corroborate
results from recent studies while also providing novel evidence for biological processes that are
differentially expressed between the PFC and NAc. Additionally, the second study is the first to
explore circRNA:miRNA:mRNA interactions in the brains of chronic alcohol abusers and the role
of circRNA as potential regulators of known AUD risk genes. Finally, we integrate genetic
information in the form of eQTL analyses to determine the clinical relevance of these findings
within the context of recent GWAS of AUD and other addiction phenotypes.
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CHAPTER 1
INTRODUCTION
Alcohol has played a pivotal role in the evolution of human civilization and is among the
most commonly used recreational drugs throughout the world [1]. As much as alcohol continues
to be a hallmark of modern society, there is no denying that chronic alcohol consumption leads to
negative health outcomes [2]. Some researchers focus on understanding health complications
associated with excessive alcohol consumption in peripheral organs (i.e. liver failure and heart
disease) [3, 4], whereas others seek to understand the neurobiological underpinnings of addictive
behaviors that lead to the development of alcohol use disorder (AUD) [5]. This research focuses
on the intersection of these two approaches by investigating transcriptomic changes that occur in
etiologically relevant brain tissue after years of chronic alcohol abuse. Through identifying
differentially expressed transcripts associated with alcohol dependence (AD), we hope to elucidate
biomarkers that can help implicate potential therapeutic targets, either as implicit AUD risk genes
or proteins/pathways sensitive to ethanol activity. While we are not the first to attempt this, this
dissertation expands upon previous postmortem brain research by comparing expression changes
between cortical and subcortical areas of the mesocorticolimbic system (MCL) from the brains of
chronic alcohol abusers. Additionally, we explore circular RNA (circRNA) and microRNA
(miRNA) as potential regulators of differential gene expression within the context of AUD.
Here, a brief outline of the study design is provided, followed by an overview of concepts
and background information that offers justification for the presented research. Next, the two
independent studies that address our overarching research aims to explore the biological processes
dysregulated within the MCL of chronic alcohol abusers via comparative transcriptomics are
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detailed. Finally, is an overview of the results from both studies and a discussion of potential
limitations while looking forward to future research possibilities.

1.1) STUDY DESIGN
Through this dissertation, we investigate transcriptomic changes associated with AUD at various
levels (circRNA, miRNA and mRNA) within the postmortem prefrontal cortex (PFC) and nucleus
accumbens (NAc) from chronic alcohol abusers. To achieve this, we performed two independent
studies with mutually exclusive hypotheses on 35 matched AD cases and controls (Table 1). It is
important to note that AD and AUD are used interchangeably throughout this dissertation, given
samples were obtained from individuals diagnosed with AD prior to the merging of AD and alcohol
abuse into the DSM-V’s AUD diagnosis [6].

Samples (n=35) 18 Cases; 17 Controls
Age 56 ± 9.6
Sex 100% Male
Brain pH 6.59 ± 0.22
Brain Weight (g) 1413.6 ± 121.25
PMI 29.8 ± 12.47
RIN PFC = 4.51±2.04; NAc = 6.85±0.84
Hemisphere 0 = left; 1 = right
Neuropathology 0 = normal, 1 = abnormal
Hepatology 0 = normal; 1 = abnormal; 9 = N/A
Toxicology 0 = normal; 1 = alcohol; 2 = other drugs; 9 = N/A
Smoking Status 0 = never; 1 = smoker; 2 = ex-smoker; 9 = N/A
Table 1: Sample demographics and covariate dummy coding.
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1.1.1) Study 1: Network preservation reveals shared and unique
biological processes associated with chronic alcohol abuse in NAc and
PFC.
The aim of this study to is to explore differentially expressed gene (DEG) networks
associated with AD and their respective regulatory mechanisms (miRNA interactions or genetic
variation) within two separate regions of the MCL, the PFC and NAc. More importantly, we
sought to identify biological processes enriched within these gene networks that are shared or
unique between the PFC and NAc. DEGs associated with AD were clustered into co-expressed
gene networks via weighted gene co-expressed network analysis (WGCNA). We then performed a
network preservation analysis to determine which of these gene networks show strong or weak
levels of conservation between brain regions. Using the same analytical approach, we identified
differentially expressed miRNA networks and interrogated their role in regulating AD significant
mRNA networks at both the network and individual transcript level. Next, the potential impact of
genetic variation on hub gene and miRNA expression was explored via expression quantitative
trait loci (eQTL) analysis. Significant findings were interpreted within the current understanding
that functional specialization differences between evolutionarily newer PFC and older, more
conserved NAc contribute to different aspects of the proposed cycle of addiction [7]. Based on
previous research, we hypothesized that we would see shared expression changes among immune
response mechanisms between brain regions [8] and that neurosignalling pathways will show more
region-specific changes based on known differences of cell composition between the cortical and
subcortical brain regions [9].

3

1.1.2) Study 2: Identifying a novel biological mechanism for alcohol
addiction associated with circRNA networks acting as potential miRNA
sponges in the nucleus accumbens of chronic alcohol users.
This pilot study provides the first look into circRNA expression in the human brain and its
potential role in regulating DEGs associated with AD. While circRNA can impact the expression
of genes through various mechanisms, we focus on their role as miRNA sponges. For this analysis,
we follow an analytical pipeline similar to the previous study. Differentially expressed circRNA
associated with AD are partitioned into co-expressed networks via WGCNA and significant hubs
are extracted for downstream analyses to identify meaningful circRNA:miRNA:mRNA
interactions. Significant circRNA:miRNA:mRNA interactions within the framework of the
miRNA sponge hypothesis were explored via a series of statistical and bioinformatic tests including
correlation, non-coding RNA (ncRNA) target prediction, and moderation regression. Additionally,
we determined whether genetic factors have a significant impact on the expression of circRNA
hubs via (eQTL) analysis. Finally, we interrogated the clinical relevance of significant eQTLs by
assessing their overlap with recent GWAS of smoking and AUD. As mentioned previously, this
study is the first to identify significant circRNA networks associated with AD and outlines their
roles as miRNA sponges that can potentially regulate the expression of DEGs in a disease-specific
manner. We hypothesized that these results would show significant miRNA sponge interactions
enriched for neurobiological processes based on the understanding that circRNA are abundantly
and dynamically expressed in the brain [10].

1.2) CONSIDERATIONS
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We acknowledge that the postmortem brain samples used for this research are
representative of a unique and very specific demographic of alcohol users: individuals diagnosed
with severe AD after years of chronic alcohol abuse. That being said, we must be careful in
interpreting the causal nature of the reported results. It is difficult to know if expression changes
are predictive of AUD or in response to chronic alcohol consumption over years. To combat this,
we integrate genotypic information via eQTL analysis to isolate potential genetic risk factors for
AUD that might help us make inferences about causality. Even though these results primarily
represent biological shifts in the brain that occur in response to ethanol activity, the scientific and
clinical value of this dissertation is not diminished because differentially expressed mRNA,
miRNA, and circRNA can still serve as potential biomarkers for AUD by revealing dysregulated
biological processes underlying alcohol-facilitated synaptic plasticity and conditioning that further
reinforce alcohol abuse and relapse.
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CHAPTER 2
BACKGROUND
2.1) Alcohol Use Disorder (AUD)
AUD is a debilitating psychiatric illness with negative health, economic and social
consequences affecting nearly 15.1 million adults worldwide [11, 12]. AUD specifically is
diagnosed in individuals who meet two or more of the DSM-V criteria over the course of one year,
with severity (mild, moderate, and severe) determined based on the number of criteria endorsed
[13]. As mentioned previously, the DSM-IV defined diagnoses of AD and alcohol abuse were
combined in the DSM-V to form a single AUD diagnosis based on the belief that alcohol
dependence and abuse are not mutually exclusive; often times dependence cannot exist without
abuse and vice versa [6]. Depending on specific individual differences, the dangers of chronic
alcohol use are enhanced by ethanol’s qualities as a highly addictive substance [14]. The
framework for understanding how recreational alcohol use transitions to AUD follows various
models of addiction [7]. Specifically, it is believed AUD development follows three distinct stages
of addiction, each with their own hypothesized neurobiological mechanisms: binge/intoxication;
withdrawal/negative affect; and preoccupation/anticipation (i.e. craving) [15]. Within this cyclical
model of addiction, two brain regions, the PFC and NAc, are believed to play different roles in the
development of AUD as part of the larger MCL [16, 17]. Specifically, the PFC is important for
executive functioning and has been linked to the preoccupation/anticipation stage, whereas NAc
based allostatic conditioning of reward response is associated to both binge/intoxication and
withdrawal/negative affect [7]. While the current model of alcohol addiction is useful for
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understanding neuroanatomical correlates of the broader behavioral adaptations associated with
AUD, most of the molecular underpinnings for these functional processes remain unknown.

Figure 1: The mesocorticolimbic system and cycle of addiction. Visual representation of the
dopaminergic mesocortical and mesolimbic pathways connecting the VTA to the PFC and NAc as well
as an outline of the three stages of addiction as proposed by Koob and Volkow [18].

2.2) Mesocorticolimbic System and AUD
Chronic alcohol use, and more specifically AUD, leads to widespread damage to vital
organs as the body constantly metabolizes ethanol, effectively increasing the risk of liver disease
and cardiomyopathy [19]. In addition to affecting digestive and cardiovascular systems, ethanol
and its metabolites have a substantial impact on brain chemistry and associated neurobiology. The
MCL, connecting the ventral tegmental area (VTA) to the PFC and NAc (Figure 1), has proven
especially susceptible to alcohol associated neuroadaptations [20, 21]. The functional specialization
of the MCL in conjunction with postmortem brain research can link alcohol sensitive
neurobiological mechanisms to AUD specific behaviors. For example, alcohol facilitated
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disruption of the PFC can result in an impaired response inhibition, a hallmark of addictive
behaviors [22]. In contrast, positive reinforcement mechanisms of reward seeking is regulated by
the mesolimbic pathway via increased firing rates of dopaminergic neurons within the VTA and
NAc [23]. Over time, alcohol induced mesolimbic conditioning and dysfunction can lead to
increased incentive salient (wanting) behaviors and the development of AUD [15]. Alcohol
associated dysfunction of the MCL creates the complex behavioral network that reinforces alcohol
cravings based on emotional memory processing, reward conditioning, and a lack of impulse
inhibition regardless of negative health or social consequences [24]. Little is known about the
molecular mechanisms underlying these functional processes or if these mechanisms are conserved
between cortical and subcortical MCL structures. Thus, the goal of Study 1 is to elucidate the
predicted biological function associated with DEG networks shared or unique to the PFC and NAc.

2.3) Molecular Targets of Alcohol
Ethanol, the main alcohol present in wine, spirits and beer, is a relatively simple two-carbon
molecule (C2H5OH) which primarily interacts with other biomolecules via weak hydrophobic
interactions and hydrogen bonding [25]. Unlike other drugs of abuse, alcohol lacks specificity in
its neuronal binding profile and is easily able to traverse cell membranes, interacting directly or
indirectly to both intercellular and intracellular molecular targets [26]. The most commonly
understood direct molecular targets for ethanol is alcohol dehydrogenase (ADH) and aldehyde
dehydrogenase (ALDH) which are responsible for the primary and secondary oxidization of
alcohol into its respective aldehydes and ketones [27]. While ADH facilitated alcohol metabolism
predominantly occurs in the liver, alcohol in the brain is converted into acetate by the catalase and
cytochrome P450 2E1 (CYP2E1) enzymes [28]. Among the proteins responsible for ethanol

8

metabolism, genes within the ADH cluster along with ALDH2 have been robustly associated with
AUD in multiple genome-wide association studies (GWAS) [29–31]. These single nucleotide
polymorphisms (SNPs) have been shown to lead to deficits in alcohol metabolism, effectively
serving as a protective factor for AUD by increasing the negative side effects of alcohol
consumption [32].
Direct and indirect ethanol targets in the brain are much more ambiguous and centered
around proteins primarily associated with synaptic transmission and plasticity. More specifically,
two types of signaling pathways have been shown to be important for regulating addictive
behaviors through either reinforcing excessive drinking, craving and relapse (“go” pathways) or
protecting against excessive activation of the go-pathway (“stop” pathways”) [33]. The “go
pathway” in the brain is primarily mediated by the activity PKA (protein kinase A), FYN (tyrosine
kinase fyn), and HRAS. Alcohol leads to activation of PKA through interacting with adenylyl
cyclase (AC) which in turn leads to the increased activation of adenosine and dopamine Gsacoupled protein receptors (A23R and DR1 respectively) [34]. FYN is activated through the
phosphorylation and subsequent inactivation of STEP by PKA, resulting in enhanced NMDAR
and CaMKII mediated AMPAR activity [35–37]. Alcohol also indirectly impacts HRAS via
interactions with PKA and RAS-specific guanine nucleotide-releasing factor 1/2 (RAS-GRF1/2)
[38, 39]. HRAS activation begins a downstream signaling cascade to various proteins (ERK1/2,
mTORC1, and AKT) that support the transcription/translation of genes associated with
microtubule assembly and postsynaptic density organization [34]. In summary, alcohol associated
activation of the “go” signaling pathway results in altered synaptic plasticity resulting from the
conditioning of reward response and emotional memory processing as individuals experience
positive affect while drinking followed by negative affect during withdrawal. This cycle, thus,
reinforces continued/excessive alcohol consumption and relapse. The “stop” pathway is important
9

for regulating the over-activation of the go pathway mainly through the activity of BDNF/GDNF
during periods of moderate, but not excessive alcohol consumption [33]. While the exact
mechanism by which this pathway regulates excessive alcohol consumption is relatively unknown,
evidence from animal models show that moderate drinking leads to increased BDNF expression
[40, 41], with other experimental studies indicating that either the overexpression or knockout of
BDNF can lead to decreased or increased alcohol consumption respectively [42, 43]. Overall, it is
believed that individual differences in respect to the activity/expression of these neurotropic factors
is important for determining why some people who drink to excess develop AUD, when others do
not [44]. Within the context of this research, we are interested in exploring if the dysregulation of
these neuronal mechanisms/pathways primarily studied in animal models are translatable to the
postmortem brain transcriptome of chronic alcohol abusers.

2.4) Utility of Human Postmortem Brains
It is important to study the molecular consequences of chronic alcohol abuse in etiologically
relevant brain tissue so we can better understand the complex biological underpinnings of AUD.
While proxy tissues such as model organisms, blood, or cell cultures have been used to understand
the molecular underpinnings of substance use disorders, they provide little explanation for the
complex behavioral adaptations we often associate with addiction in humans. Within the context
of AUD, none of these models recapitulate the complexity of neurophysiological changes that
occur after chronic alcohol use or how the complex interaction of genetic and environmental
factors can help predict neurobiological outcomes. The human brain is characterized by relatively
high levels of expression when compared to other non-neuronal tissues [45, 46] and/or the brains
of mammalian model organisms [47–50]. Additionally, the observed transcriptome complexity is
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greater within the human brain, which is reflected by higher levels of alternative isoforms and an
increased magnitude of alternative splice events when compared to other tissue types [51–53].
The complex nature of assessing specific psychological symptoms associated with AUD is
not easily translatable to model organisms. For instance, animal studies rely on loose behavioral
models to simulate desired phenotypes [54] which does little to recapitulate the internalizing and
externalizing symptoms that promote relapse during periods of withdrawal [55]. While some
models have been validated though extensive research, e.g. stress-based tests for modeling anxiety
like behaviors [56–58], there are limited paradigms for modeling impulsivity and other personality
based risk factors for AUD and other SUDs [59]. Additionally, the lack of meaningful model
systems for replicating the complex behaviors associated with AUD is exacerbated by an often comorbid psychiatric diagnosis among chronic alcohol abusers [60]. With that being said, our current
understanding of the molecular underpinnings of addiction and AUD are derived primarily from
model organisms. This is due to the increased experimental control within model systems [61] and
the overall limited availability of postmortem brain tissue from AUD cases [62]. Here, the
transcriptome is profiled at multiple levels (circRNA, miRNA, and mRNA) within etiologically
relevant postmortem brain tissue to yield novel findings about the molecular underpinnings of
AUD previously unexplored in proxy tissues.

2.5) Utility of Gene Expression Studies
Among the cascade of biological changes important for disease development, gene
expression serves as an important biological intermediate between genetic predisposition and
protein function. Most modern approaches for assessing gene expression are adapted from
methodology used for identifying sequence variation within a targeted loci [63]. For decades, the
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“gold” standard approach for targeted gene expression analysis and experimental validation of
microarray and RNA-seq has been reverse-transcriptase quantitative PCR (RT-qPCR) [64]. RTqPCR works by converting RNA to complementary DNA (cDNA) through the use of a reverse
transcriptase which can be quantified via PCR by comparing the exponential growth of
amplification against a stable “housekeeping” gene [65]. With advancements in genome-wide
sequencing technologies, methods for quantifying gene expression have evolved in parallel. Among
the most predominantly used methods of assessing genome-wide expression levels (microarray and
RNA-seq) here, microarray is used to assess transcript abundance at three different levels
(circRNA, miRNA, and mRNA). Gene expression microarrays are based on the principles of
cDNA synthesis and nucleic acid hybridization to assess the expression of thousands of transcripts
in parallel [66]. Once gene expression has been quantified, researchers employ a variety of
network based approaches to meaningfully interpret differential expression [67]. WGCNA is one
of the most commonly used network based methods in which large sets of DEG are partitioned
into modules containing transcripts with correlated expression [68]. From these co-expressed
modules, researchers are able to identify gene networks enriched for biological processes relevant
to the phenotype of interest [69], as well as isolate highly intramodular connected hub genes, which
serve as predicted drivers of expression for entire modules [70]. Finally, gene expression has the
additional benefit of providing potential functional explanations for diseases associated genetic
variants identified in GWAS via eQTL mapping [71]. In eQTL studies, gene expression levels
treated as quantitative traits are mapped to genetic variants either within 500kb of the transcription
start site (cis-eQTL) or across the entire genome (trans-eQTL) [72]. While the utility of gene
expression goes beyond what is presented here, this dissertation utilizes microarray, WGCNA, and
cis-eQTL analyses to gain insight into the molecular underpinnings of AUD within the
postmortem brains of chronic alcohol abusers.
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2.6) Gene Expression and AUD
Transcriptomic profiling of postmortem brains can provide valuable insight into the
biological consequences of chronic alcohol abuse while also providing functional explanations for
genetic variants associated with AUD. While most studies observe relatively small fold changes
when comparing expression differences between AUD cases and controls, about 20-50% of the
transcriptome is differentially expressed [73]. Because of small effect sizes, gene expression studies
have limited power to interpret the importance of individual genes in respect to AUD etiology.
Network based approaches such as WGCNA, however, aggregate related genes into co-expressed
networks to allow for the identification of specific biological processes that are dysregulated in the
postmortem brains of chronic alcohol abusers [68, 74–76]. Studies show the most notable DEG
networks associated with AUD are linked to immune/stress response, synaptic plasticity, and
neurotransmission. More specifically, studies from our lab and others have shown that
immune/inflammatory genes are upregulated throughout the brain of chronic alcoholics, which is
believed to be a product of the cellular response to ethanol’s neurotoxic properties [74, 77]. While
our understanding of how immune/stress response reinforces addictive behaviors is limited, it is
suggested that stress-induced signaling is important for the negative affect states often associated
with withdrawal, thus leading to conditioning that promotes relapse [8].
Aside from immune response mechanisms, we see the dysregulation of genes important for
synaptic transmission and neuroplasticity. Multiple studies have shown decreased expression of
GABAA and GABAB subunits within the hippocampus and PFC of alcoholics [78, 79]. GABAergic
receptors play an important role at each step in the previously mentioned cycle of addiction by
regulating reward response in the NAc and hippocampus [80]. Ionotropic and metabotropic
glutamate receptors, as previously mentioned, are important for the development of AUD through
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modulating the release of dopamine during periods of intoxication, leading to the formation of
alcohol dependent synaptic connections [81]. Postmortem brain studies have shown the significant
upregulation of NMDAR and AMPR subunits in the PFC of individuals diagnosed with AD [78,
82]. The same study [82] also identified increased expression of genes (GIPC1 and MIB2) involved
in the trafficking and ubiquitination of NMDAR subunit 2B [83, 84]. Ethanol’s ability to promote
glutamate activity in the brain at NMDAR and AMPR is important for neurogenesis that promotes
relapse and continued alcohol abuse despite negative consequences [85]. This dissertation builds
upon these recent findings by determining transcriptome changes associated with AUD that are
either conserved or unique to the PFC and NAc.

2.7) MiRNA Biogenesis and Function
Another class of molecules that have been extensively studied using postmortem brain tissue
from cases with various neuropsychiatric and substance use disorders (SUDs) are miRNA. These
are small non-coding RNA (≈22 base pair), the biogenesis of which is a three-step process starting
in the cell nucleus and ending with the generation of the mature miRNA in the cytoplasm [86].
The primary miRNA transcript measuring over 1kb in length is cleaved in the nucleus to form an
intermediate molecule called precursor miRNA (pre-miRNA). The pre-miRNA is exported to the
cytoplasm, where it is further cleaved and loaded onto the RNA-Induced Silencing Complex
(RISC) to generate the mature miRNA sequence [87]. Most miRNA regulate gene function
negatively through imperfect binding with the 3' untranslated region (3’UTR) of mRNA [88, 89].
Animal miRNAs pair with 3’UTR of their target genes though the “seed” region (consisting of
nucleotides 2-7) at the 5' end of the mature strand. Depending on homology, miRNA can impact
an mRNA target either through degradation or translational inhibition [90]. It has been estimated
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that miRNAs may influence as much as 30% of the human transcriptome [91]. MiRNA further
contribute to the transcriptome complexity of the brain. Aside from being highly enriched in the
brain [92, 93], miRNAs have been shown to be potential biomarkers for psychiatric disorders and
more specifically AUD [94, 95]. Our lab and others have made strides in profiling miRNA
expression and identifying co-expressed miRNA-mRNA networks within the postmortem brains
of chronic alcohol users [74, 96]. These studies combined with studies from animal models have
revealed alcohol associated dysregulation of miRNAs with mRNA targets important for immune
response and synaptic function [97, 98]. Here we attempt to expand upon this previous research
by comparing AD significant mRNA:miRNA interaction networks between brain regions (NAc vs.
PFC) to better understand how miRNA regulate addiction related biological processes.
Additionally, we explore miRNA within the framework of circRNA:miRNA:mRNA interactions
to provide a regulatory mechanism for genes associated with AUD.

2.8) Circular RNA
With the recent technological advancements in the study of transcriptomics circRNA have
emerged as important ncRNA with implications for gene regulation and disease. CircRNA are
unique from miRNA and most other ncRNA in that they form circular secondary structures,
resulting in increased stability [99]. The biogenesis of circRNA consists of spliceosome-mediated
canonical splicing followed by backsplicing of pre-mRNA in which the 5’ and 3’ ends of spliced
exons/introns are covalently bonded to form a closed end loop structure [100]. CircRNA have
been reported to alter the expression of their host mRNA as well as the expression of distal genes
through various mechanisms [10]. Study 2 focuses solely on the mechanism by which circRNAs
act as miRNA sponges in order to alter the expression of target genes in a disease dependent
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manner. As mentioned previously, miRNA can lead to the translational repression and/or
degradation of target mRNAs by interacting with the 3’UTR [101]. CircRNA act as a competitive
endogenous RNA (ceRNA) by sequestering homologous miRNAs that would otherwise interact
with their target mRNA, effectively increasing the expression of the target gene [102]. Within the
context of AUD and other neuropsychiatric disorders, circRNA is of particular interest for
researchers based on their dynamic and abundant expression within the mammalian brain [103].
Additionally, the transcriptional landscape of circRNA in the brain is more diverse relative to other
tissues, with one study identifying 141 of the 339 profiled circRNA were unique to the cerebral
cortex [104]. Among these circRNA, several are derived from host genes important for neuronal
function that have been significantly associated with alcohol use in previous studies (HOMER1, and
NTRK2) [105, 106]. Given the study of circRNA is still in its infancy, researchers do not fully
understand how circRNA interact with neurobiological systems to contribute to the etiology of
AUD and other psychiatric disorders. While differentially expressed circRNA have been associated
with both alcoholic liver disease and cardiomyopathy in animal models [107–109], to the best of
our knowledge, Study 2 provides the first profiling of circRNA expression in the postmortem
brains of chronic alcohol abusers. More specifically, this dissertation provides the framework for
investigating circRNA networks associated with chronic alcohol abuse and their predicted function
in regulating AUD risk genes via miRNA sponge interactions.
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CHAPTER 3
STUDY 1: Network preservation reveals shared and unique
biological processes associated with chronic alcohol abuse in
NAc and PFC.
3.1) INTRODUCTION
AUD is a debilitating psychiatric illness with negative health, economic, and social
consequences for nearly 15.1 million affected adults worldwide [12]. AUD risk is dependent upon
both genetic and environmental factors, with a heritability of 0.49 [110]. The neurobiological
framework for understanding how benign, recreational alcohol use leads to AUD follows various
hypotheses [34, 111, 112], with the most commonly accepted being the cyclical model of addiction
[18]. This hypothesis provides valuable insight into the functional specialization of different brain
regions that underlie behavioral maladaptations associated with AUD [15]. However, the genetic
architecture and molecular mechanisms contributing to alcohol-facilitated neuroadaptations
remain widely unknown.
Postmortem brain studies provide the unique opportunity to interrogate neurobiological
changes associated with addiction across brain regions and neural pathways [113, 114]. Among
these, the MCL, which connects the VTA to the PFC, and NAc, has proven especially sensitive to
alcohol-associated neuroadaptations [16, 17, 115]. Recent postmortem brain studies of AUD have
focused on examining gene and miRNA expression as the biological intermediate between genetic
variation and molecular function [74–76, 116–119]. Studying mRNA and miRNA interactions
may also reveal functional relationships that mediate the differential expression of risk AUD genes
based on the role miRNAs play in the destabilization and degradation of their target genes [101].
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While single gene expression differences are continuously explored, network approaches, such as
WGCNA, allows genes with correlated expression, and therefore likely related functions, to cluster
into modules that then can be analyzed to identify dysregulated biological processes and molecular
pathways associated with AUD [120]. Others and we have successfully implemented this method
to identify gene networks associated with AUD within the MCL and other brain regions [74, 75].
While postmortem brain expression differences alone are insufficient to infer a causal relationship
between AUD and neurobiological function, the integration of genetic information via eQTL
analysis can help elucidate the regulatory mechanisms by which genetic variants associated with
AUD impact gene expression [121].
Thus, in this study, we seek to expand upon previous research by jointly analyzing two key
MCL areas, the NAc and PFC, to identify unique and shared neurobiological processes associated
with AD. To achieve this, we utilize a case/control study design to identify genes and co-expressed
gene networks associated with AD. We then performed a network preservation analysis to
determine how well significant modules and their respective biological processes are conserved
between the PFC and NAc of chronic alcohol abusers. Within the significant modules, we identified
the most connected genes (termed hubs), which were then integrated with miRNA expression data
analyzed using the same methodological framework. Finally, we assessed the genetic factors that
might impact the functions of risk AD genes via eQTL. The miRNA and eQTL analyses were
performed in order to identify the regulatory mechanisms by which gene networks identified in
PFC and NAc contribute to alcohol addiction.

3.2) MATERIALS AND METHODS
3.2.1) Tissue Processing and RNA Extraction
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Postmortem brain tissue from 41 AD cases and 41 controls was provided by the Australian
Brain Donor Programs of New South Wales Tissue Resource Centre (NSW TRC) under the
support of The University of Sydney, National Health and Medical Research Council of Australia,
Schizophrenia Research Institute, National Institute of Alcohol Abuse and Alcoholism, and the
New South Wales Department of Health [113]. Samples were excluded based on: (1) history of
infectious disease, (2) circumstances surrounding death, (3) substantial brain damage, and (4) postmortem interval > 48 hours. Total RNA was isolated from PFC (the superior frontal gyrus) and
NAc tissue using the mirVANA-PARIS kit (Life Technologies, Carlsbad, CA) following the
manufacturer’s suggested protocol. RNA concentrations and integrity (RIN) were assessed via
Quant-iT Broad Range RNA Assay kit (Life Technologies) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Inc., Santa Clara, CA) respectively. Samples were matched for RIN, age, sex (all
male), ethnicity, brain pH, and post mortem interval (PMI) as part of a previous study [74] yielding
a total of 18 case-control matched pairs (n=36). Due to our matching, the RINs in PFC were
slightly lower (mean=4.5, ±2.04) compared to NAc (mean=6.9, ±0.84). Previous reports, however,
have demonstrated that in post-mortem brain studies reliable results are readily obtained even with
RINs ≤4 [122]. For demographic information see Appendix I.

3.2.2) Gene Expression Microarray and Data Normalization
Gene expression was assayed using Affymetrix GeneChip Human Genome U133A 2.0
(HG-U133A 2.0) on 22,214 probe sets spanning ~ 18,400 mRNA transcripts, and the Affymetrix
GeneChip miRNA 3.0 microarray interrogating the expression of 1733 mature miRNAs as
previously described [123]. None of the mRNA or miRNA probes were excluded based on quality
control criteria outlined in previous studies [74]. Raw probe data were GCRMA background
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corrected, log2 transformed, and quantile normalized using Partek Genomics Suite v6.23 (PGS;
Partek Inc., St. Louis, MO) to obtain relative gene expression values. A principal component
analysis was used to identify potential outlier samples. Only one case sample was removed from
the analyses, leaving 18 controls and 17 cases (n= 35) for both brain regions. It has become widely
accepted to verify a subset of microarray-generated gene expression changes via an independent
platform such as qPCR. Considering limited tissue availability and our extensive use of the
Affymetrix platform in the past, we did not include microarray validation in this study which is
similar to what other groups have done in the past [124]. We have previously ‘validated’ the same
array and platform in independent qPCR experiments with a concordance between microarray
and qPCR platforms exceeding 80% in the past [74].

3.2.3) Analysis of Differential Gene Expression
The relationship between AD case status and gene expression in PFC and NAc was
analyzed via bidirectional stepwise regression for each gene. This approach is better suited to adjust
for the confounding effect of covariates within each transcript’s regression model than the robust
linear regression approach employed previously in the analyses of NAc [74]. The gene expression
analysis between our AD cases and matched controls was performed in RStudio (ver. 1.1.463) with
the Stats package (ver. 3.5.1) using a bi-directional stepwise regression model for both mRNA and
miRNA normalized expression data generated from NAc and PFC. The bidirectional stepwise
regression analysis cycles through all available covariates (i.e. age, RIN, pH, PMI, brain weight,
hemisphere, toxicology, hepatology, neuropathology, and smoking) to identify the best-fitting
model with the lowest Akaike information criteria (AIC) for each transcript (Mean AIC: NAc= 129.10, PFC= -71.07). We further observed that brain pH, RIN, and neuropathology were the
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most influential covariates in the analyses of NAc expression data, while RIN and smoking history
were the two most important covariates in the PFC expression analysis. Finally, we assessed
proportion of variance explained by each covariate via the variancePartition package (ver. 1.20)
[125].

3.2.4) Network Analyses
WGCNA was performed using the WGCNA package in RStudio (ver. 1.66). All nominally
significant genes (p≤0.05) were used to generate a signed similarity matrix via pair-wise Pearson
correlations. The nominal significance was chosen to (1) include genes with smaller effect sizes,
albeit true positive signals, (2) exclude genes with low disease variance, i.e., likely not associated
with AD and (3) to provide a sufficient number of genes for the network analysis. In the WGCNA,
our similarity matrix was raised to a power (mRNA b = 14; miRNA b = 6) to approximate the
scale-free topography of the adjacency matrix, in which stronger correlations are emphasized over
weaker ones. Transcript interconnectedness was determined from the calculated topological
overlay measure (TOM). The default, unsupervised hierarchical clustering method was used to
partition modules at specified dendrogram branch cut sites using the Dynamic Tree Cut method.
Highly correlated modules were then merged based on minimum merge height of r2 = .8 and
minimum module size of 35. Conventional colors were used to categorically label co-expressed
networks and the sum of relative expression within each module is represented as a single value
(module eigengene (ME)) for downstream phenotypic analysis.
MEs were correlated to AD case-status and available demographic/biological covariates.
To validate WGCNA module clustering, we performed a bootstrap based resampling of 100
iterations with replacement. Next, using WGCNA with the clusterRepro (ver. 0.9) package in
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RStudio, we identified the level of module preservation between the PFC and NAc by comparing
adjacency matrices and calculating the composite preservation statistic (Zsummary). A Zsummary >10
indicates strong evidence for network preservation, Zsummary <10 >2 indicates weak evidence of
network preservation and Zsummary <2 indicates no module preservation, as outlined previously
[126].

3.2.5) Gene Set Enrichment Analysis
Gene set enrichment was performed using ShinyGo (ver. 0.61) gene annotation database
[127]. Gene lists from the significant AD modules from NAc and PFC were enriched using GO
biological processes consisting of 15,796 gene sets from the Ensembl BioMart release 96; all pvalues for significantly enriched gene sets are false discovery rate (FDR) adjusted (FDR of 5%). We
further performed cell type enrichment using the “userListEnrichment” option within the WGCNA
package in R (ver. 1.66) as previously described [74]. Statistical significance of brain-list
enrichment was determined via a hypergeometric test; all p-values were adjusted at FDR of 5%.

3.2.6) Hub Gene Prioritization
Hub genes were defined based on the strength of intramodular connectedness, (also
referred as module membership (MM)) calculated from the absolute value of the Pearson’s
correlation coefficient between ME and expression values. Hub genes were prioritized for
downstream analysis based on MM of r≥0.80 and a significant gene correlation with AD (at p
≤0.05).

3.2.7) eQTL Analysis and GWAS/GTEx Enrichment
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DNA from the postmortem brain sample was processed and genotyped as part of a larger
GWAS study [74]. Genotypes with excessive missingness (greater than 20%) and monomorphic
for homozygous major and minor alleles were removed. We then selected only, local, cis-eQTLs,
defined as SNPs 500kb from the start/stop positions for each hub gene. Such selected SNPs were
pruned with Plink v1.9 to exclude variants in linkage disequilibrium (LD) (R2 ≥0.7). For eQTL
detection, SNP effect on hub gene expression was analyzed via MatrixEQTL package (ver. 2.2) in
R using a linear regression model adjusting for covariates. To identify potential disease risk eQTLs,
we further tested for an interaction (SNP x AD) term between genotype and AD status using the
“modelLINEAR_CROSS” argument. A significant genotype/disease interaction for a SNP/gene pair
would indicate that the effect of genotype on expression is significantly different in AD cases versus
controls. To determine the overlap between the eQTLs in our sample (at p≤0.002) and significant
GWAS hits (at p≤1E-4) from previously reported alcohol and smoking GWAS [128, 129], we
employed the Simes enrichment test [130]. We further tested the overlap between eQTLs obtained
from our analyses against eQTLs obtained from GTEx consortium [131]. The significance of this
overlap was assessed via a Fisher’s exact test at p ≤0.05 threshold. See Appendix II for a detailed
description of GWAS and GTEx enrichment.

3.2.8) mRNA/miRNA Target Prediction
The relationship between significant miRNA and mRNA modules from each brain region
was examined by performing a Pearson’s correlation on the miRNA and mRNA module MEs
using the Stats package (ver. 3.5.1) in RStudio. Significant miRNA/mRNA ME correlations (at
FDR of 5%) were followed up with a more detailed series of analyses, in which individual mRNA
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hub and miRNA expression was correlated via Pearson’s correlations using the miRLAB package
in R (ver. 1.14.3).

3.3) RESULTS
3.3.1) AD Case/Control Differentially Expressed Genes (DEG)
A bidirectional stepwise regression revealed 3,536 and 6,401 DEGs in PFC and NAc,
respectively, at the nominal p ≤0.05, of which 1,279 DEG were shared between the two regions
(Figure 2A/B). Among these, 603 and 494 genes were downregulated and upregulated,
respectively, and 182 genes were expressed in opposite directions between the two regions. Within
the DEGs in NAc, nine genes (ADH1B, ADH1C, H2AFZ, EIF4E, FTO, DRD2, SLC39A8, and
VRK2) were implicated in the largest and most recent AD GWAS [31]. At FDR of 5%, we
identified 1,841 DEG from the NAc and 70 from the PFC. The miRNA regression analysis
identified 430 and 170 nominally significant miRNAs in the NAc and PFC, respectively, with 168
miRNAs differentially expressed in NAc at FDR of 5% with no miRNA reaching FDR significance
in PFC. To maintain an identical analytical pipeline for both brain regions and optimize the
selection for the most influential confounding factors, we co-jointly analyzed the PFC expression
data generated in this study with our previously published NAc expression data [74]. We observed
a highly significant overlap between the DEGs identified in NAc from both studies (Fisher’s exact
test, p=1E-10). When we assess each covariate’s contribution to the overall gene expression
variance, we see that the impact of any given covariate is highly variable depending on the gene
(Figure 2C/D). This helps validate our approach for utilizing a different set of covariates for each
gene’s regression model in order to control for confounds that contribute to the highest proportion
of the variance.
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Figure 2: Volcano plots and variance partitioning of differentially expressed mRNA from NAc and
PFC. A) NAc regression analysis reveals 6,401 DEG at the nominal p≤0.05 and 1,841 after FDR 5%
correction. B) PFC regression shows 3,536 DEG at p≤0.05 and 70 after FDR 5% correction. Violin plot of
each covariate’s percent contribution to the variance for NAc (C) and PFC (D) gene expression.

3.3.2) mRNA Gene Network Module Clustering
In NAc, at a Bonferroni adjusted p≤0.05, we identified 6 modules significantly correlated
with AD case status (Figure 3A). Among these, NAcdarkgreen was the only negatively correlated
module, whereas NAcdarkorange, NAcpurple, NAcmagenta, NAcskyblue, and NAcgreenyellow were all positively
correlated with AD cases relative to controls (Figure 3B). In PFC, we identified 3 modules
significantly correlated to AD at Bonferroni adjusted p≤0.05 (Figure 3C). Of these, the PFCpink
module was negatively correlated, while PFCdarkred and PFClightgreen were positively correlated with
AD cases (Figure 3D). To assess the validity of these network modules, we performed a bootstrap
resampling that showed consistent module clustering when compared to the original gene networks
(Figure 4).
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Figure 3: WGCNA clustering and module-trait relationships. A) NAc cluster dendrogram and module
assignment with dissimilarity based on topological overlap. The 6,401 selected transcripts were
clustered into 23 distinct modules. B) NAc module-trait relationship heatmap correlating (Pearson’s)
module MEs with AD diagnosis and covariates. Uncorrected p-values are given in parenthesis below
each correlation coefficient. 6 AD associated significant modules (NAcdarkgreen, NAcdarkorange, NAcgreenyellow,
NAcmagenta, NAcskyblue, and NAcpurple,) were identified after Bonferroni correcting p-values (*=p≤0.05). C) PFC
cluster dendrogram and module assignment. The 3,536 selected transcripts were clustered into 17
different co-expressed modules. D) PFC module-trait relationship heatplot created as previously
described. We identified 3 AD associated modules (PFCpink, PFCdarkred, and PFClightgreen) after Bonferroni
correcting p-values (*= p≤0.05).
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Figure 4 : Robust mRNA module clustering dendrogram. To ensure network robustness and minimize
the potential effect of outlier samples on network structure, we used the robust ‘bootstrapped’ version
of WGCNA (rWGNCA). We performed 100 iterations in which networks were created after randomly
subsetting 2/3 of the total sample. The resulting 100 networks were merged into one large, final
consensus network with the individual sub-networks showing reasonably high consistency with the
final networks. A) NAc. B) PFC.

3.3.3) NAc and PFC Network Preservation
We performed a network preservation analysis to determine how well co-expressed
networks from the PFC are conserved in NAc and vice versa. We focused primarily on the Zsummary
and Median Rank network preservation statistics because Zsummary estimates network overlap by also
taking into consideration network connectivity. Median Rank being invariant to module size,
provides a more accurate estimate of network preservation since larger networks tend to be more
conserved due to their size alone. We observed that NAcdarkorange and NAcpurple showed little to no
network preservation (Zsummary <2), NAcskyblue, NAcdarkgreen, PFCdarkred, and PFCpink showed moderate
levels of network preservation (2< Zsummary <10), and NAcgreenyellow, NAcmagenta, and PFClightgreen showed
high levels of network preservation (Zsummary >10) (Figure 5A/B). For detailed information about
the individual density and connectivity statistics that were used to create the composite network
preservation statistics, see the Appendix III.
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Figure 5: Network preservation and gene-set enrichment. A) NAc Z-summary statistic calculated as
an aggregate of network preservation statistics (Preservation level: high = Z>10; moderate = 2<Z<10;
low = Z<2) with color corresponded top-10 most significant (-log10(FDR) transformed) GO biological
processes for significant AD associated modules. B) PFC Z-summary statistic and corresponding GO
biological processes term (-log10(FDR) transformed). C) Venn-diagram of the shared transcripts from
highly preserved NAc modules (NAcmagenta and NAcgreenyellow) and their corresponding significant PFC
modules (PFClightgreen and PFCdarkred). D) Brain cell type gene-set enrichment from the NAc and PFC (log10(FDR) transformed). Colors correspond with their respective modules (NAcgreenyellow, NAcmagenta,
NAcdarkgreen, PFCpink, PFCdarkred, and PFClightgreen) with single gene sets enriched in modules.
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3.3.4) Biological Processes and Cell-type Enrichment
To gain perspective on the biological underpinnings of the significant gene networks from
NAc and PFC, we performed a gene-set enrichment analysis, gene ontology (GO) biological
processes annotation (ShineyGO ver.61) and neuronal cell type enrichment for the two regions. As
one of our aims was to identify unique and shared gene networks associated with AD in NAc and
PFC, we focused our analyzes on NAc modules that were highly (i.e., NAcgreenyellow and NAcmagenta)
and poorly (i.e., NAcdarkorange, and NAcpurple) preserved in PFC. NAcgreenyellow and NAcmagenta are
primarily associated with the immune response process (FDR ≤0.05) believed to be a consequence
of neurotoxicity caused by chronic alcohol abuse (Figure 5A). These modules are enriched among
microglia and astrocyte cell types (FDR ≤0.05), which is expected based on the functional
properties of the glial cells (Figure 5D). The poorly preserved NAc modules showed enrichment
within gene-sets associated with cilia-based cell projection and cell morphogenesis (FDR≤0.05)
(Figure 5A).
Corollary, we performed gene-set enrichment analysis on the PFC modules, which were
highly and poorly preserved in NAc. (Figure 5B). Similar to the NAcgreenyellow and NAcmagenta modules,
the highly preserved PFClightgreen module was associated with immune response processes (FDR
≤0.05) and significant microglial cell type enrichment (FDR ≤0.05) (Figure 5D). PFCdarkred and
NAcmagenta, were moderately preserved with each other (Figure 5C) with PFCdarkred showing astrocyte
cell type enrichment (Figure 5D). Interestingly, a class of genes in one family of immune response
proteins, metallothioneins (MTs), contained in both the PFCdarkred and NAcmagenta modules, were
differentially expressed in both brain regions between cases and controls (Figure 6). Since hubs are
considered the most important genes for preserving the network’s integrity, when these analyses
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were further limited only to the hub genes, not surprisingly, we captured the same GO terms and
biological process that we observed from the entire module gene lists.

Figure 6: Metallothionein gene expression. Relative expression of 8 metallothionein cluster genes
(MT1E, MT1F, MT1G, MT1H, MT1HL1, MT1X, MT2A, and MT3) comparing AD case to controls for both
the NAc and PFC. P-values presented for each transcript are based on our bidirectional stepwise
regression.
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3.3.5) Hub Genes of Potential Biological Significance
To identify candidate hub genes of potential biological significance, we focused on the
relationship between intramodular connectivity (i.e., MM) and gene significance (GS) to AD case
status. Of the 459 genes from the 3 significant PFC modules and the 6 significant modules in NAc,
we identified 99 and 433 unique hub genes with MM ≥0.80, respectively (Figure 7). We focus on
the hub genes due to their biological relevance to AD and predicted role as drivers of expression
for the entire module [70].
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Figure 7: Hub gene prioritization based on module membership (MM) and gene significance (GS)
for AD. A) Our analysis of the 1,843 transcripts within the six AD correlated modules from the NAc
revealed a total of 433 unique candidate hub genes (MM ≥ 0.80). B) The three AD correlated modules
from the PFC include 459 transcripts and 99 hub genes (MM ≥ 0.80).
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3.3.6) Detection of miRNA Gene Network Modules in NAc and PFC
In NAc and PFC, we identified miRNA modules with varying levels of significant
correlation to AD case status. The NAc miRNA data revealed 430 nominally significant loci, which
clustered in 5 modules ranging from 18 (NAcmigreen) to 259 (NAcmiturquoise) loci in size, of which, at
Bonferroni adjusted p ≤0.05, three miRNA modules remained significantly correlated to AD
(NAcmiyellow, NAcmibrown, and NAcmiturquiose). Of these, NAcmiyellow and NAcmibrown were negatively
correlated, whereas NAcmiturquoise was positively correlated within AD (Figure 9A). The 170 miRNA
transcripts from the PFC clustered into 6 modules ranging in size from 9 (PFCmired) to 55 miRNA
transcripts (PFCmiturquoise), of which PFCmiyellow and PFCmired, remain significant at Bonferroni
adjusted p ≤0.05; both miRNA modules were negatively correlated with AD (Figure 9D).

Figure 8: Volcano plots of differentially expressed mRNA from NAc and PFC. A) NAc regression
analysis reveals 430 differentially expressed miRNA at the nominal p≤0.05which were used for
downstream analyses. B) PFC regression shows 170 differentially expressed miRNA at p≤0.05.
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3.3.7) MiRNA Networks Show Unique Patterns of Regulation
In an attempt to identify a higher order system, network levels of interactions, existing
between the AD significant mRNA and miRNA modules we correlated their respective module
MEs. From the NAc, we identified 2 significant positive mRNA/miRNA ME correlations and 4
negative ME correlations at Bonferroni adjusted p ≤0.05 (Figure 9B). To better understand the
biological function of miRNA/mRNA interacting networks at specific loci, we honed on the
interaction between individual miRNA/gene pairs. After correlating individual mRNA hubs and
miRNA, we identified 1,801 significant mRNA/miRNA interactions (FDR ≤0.10) spanning 318
genes and 68 miRNA loci (S9 Table). Interestingly, we observed 97% (35/36) of the purple mRNA
module hub genes to be negatively correlated with either mir-449a or mir-449b from NAcmibrown
(Figure 9C). In PFC, we identified one positive mRNA/miRNA ME correlation and 3 negative
correlations at Bonferroni adjusted p≤0.05 (Figure 9E). Individual mRNA/miRNA interaction
analysis from the PFC revealed 6 mRNA/miRNA interactions (FDR of ≤0.10) spanning 6 genes
and one miRNA transcript, mir-485-5p.
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Figure 9: MiRNA WGCNA and mRNA:miRNA interaction. A) NAc miRNA cluster dendrogram and
module assignment with module-trait relationship heatmap, both as previously described in Figure 3.
B) Bonferroni adjusted significant (p≤0.05) NAc mRNA/miRNA module ME correlations (Pearson’s).
Alcohol and control groups are separated by color to emphasize sample clustering. C) Significant
(FDR≤0.05) correlation (Pearson’s) between mir-449a and selected mRNA transcripts from the low
network preserved NAcpurple module. D) PFC miRNA cluster dendrogram module assignment along with
module-trait relationship heatmap. E) Bonferroni adjusted significant (p≤0.05) NAc mRNA:miRNA
module ME correlations (Pearson’s).
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3.3.8) Brain Region Specific eQTL Regulation of Differential Gene
Expression
In NAc, we detected a total of 36 mRNA eQTLs spanning 17 unique genes and 9 miRNA
eQTLs covering 4 different miRNA (FDR ≤0.10). Of the 17 hubs with significant eQTLs, 7 are
from NAcdarkgreen (VRK1, INPP4A, HMP19, DKK3, PCDH8, RNF34, and RASGRP1), 4 from
NAcgreenyellow (FCGR3A, CTSS, AASS, and RNASE4), 3 from NAcdarkorange (DNALI1, CCDC81, and
SPAG6), 2 from NAcpurple (HIVEP1 and GNAS), and one from NAcmagenta (VAMP5). Within the PFC
we identified 34 eQTLs spanning 16 unique genes and 18 miRNA covering 7 different miRNA
transcripts (FDR ≤0.10). Of these, 11 genes are from PFClightgreen (SERPINH1, CDKN1A, PNP,
EMP1, FKBP5, IL4R, TNFRSF10B, RTEL1/TNFRSF6B, SERPINA1, MAFF, and SERPINA2) and
5 from PFCpink (GAD2, ACTL6B, KCNF1, SEZ6L, and EFNB3). Among our significant eQTLs, we
highlight two examples: FCGR3A:rs12087446 (NAc p= 3.24E-07; PFC p= 0.002) from the highly
conserved NAcgreenyellow module and DNALI1:rs12119598 (NAc p= 1.94E-09; PFC p=0.150) from
the poorly conserved NAcdarkorange module. The brain region specific eQTL impact on the expression
of these two genes suggests that different genetic mechanisms are likely at play in NAc and PFC
that may further shed light on the different behavioral measures encoded by the two brain regions
(Figure 10). For the full list of cis-eQTL, please refer see Appendix IV. To highlight the potential
clinical importance of our findings and provide functional support for previous genetic studies, we
also tested for enrichment of our clinically relevant eQTLs (i.e., testing only SNPs that showed a
significant (SNP x AD) interaction term) and previously published GWAS of addiction phenotypes.
While the overlap did not reach formal significance, likely due to the smaller GWAS sample size,
we nevertheless observed suggestive enrichment, i.e., GWAS & Sequencing Consortium of Alcohol
and Nicotine Use (GSCAN) drinks per week p=0.195; GSCAN smoking initiation p=0.251;
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GSCAN smoking cessation p=0.147; and Collaborative Study on the Genetics of Alcoholism
(COGA)+Irish p=0.299. Finally, we attempted to replicate all eQTLs in our study, irrespective of
their potential disease relevance, in the GTEx database using the Fisher’s exact test. Interestingly,
we observed a significant overlap between our eQTLs detected in the PFC (n=2,368, 6.6% of
eQTLs tested, p=0.003), but not in the NAc (n=5,436, 3.4% of eQTL tested, p=1).

Figure 10: Cis-eQTL analysis. A) Cis-eQTL boxplot directly comparing AD case/control designation with
the FCGR3A:rs12087446 eQTL from the high network preservation NAcgreenyellow/PFClightgreen module and
the DNALI1:rs12119598 eQTL from the low preservation NACdarkorange module, the relative expression is
presented on the y-axis and SNP/genotype on the x-axis. B) Alternative boxplot visualization of the same
cis-eQTL directly comparing differences between brain regions.
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3.4) DISCUSSION
AUD continues to be a growing public health concern with a complex and poorly
understood etiology as recreational alcohol use becomes habitual and problematic. The broad goal
of this study is to identify the neurobiological processes associated with chronic alcohol use via
analyzing brain region-specific gene networks from the NAc and PFC. To understand the human
behavior leading to addiction, it is important to investigate how chronic alcohol use impacts
expression changes in the evolutionarily newer cortical areas, in contrast to the older, more
evolutionarily conserved subcortical brain regions [132]. Here, we attempt to understand the
neurobiological underpinnings of alcohol specific reward conditioning in the NAc and disruption
of executive function within PFC [18] through identifying gene networks and biological processes
associated with AD that are conserved or unique to each brain region. Additionally, we assessed
the relationship between the miRNA and mRNA networks significantly correlated to AD based
on the miRNA functions to induce mRNA degradation and/or translational inhibition. Finally,
we tested the impact of genetic variants on gene expression in a disease dependent manner via ADmediated eQTL analysis.
Our network analyses are consistent with previously published reports by others and us,
showing the upregulation of immune response mechanisms among AD cases as a byproduct of
alcohol’s neurotoxic effects [8]. The immune-related modules show significant enrichment for both
astrocyte and microglial cell types, which has been validated by previous alcohol studies and the
known immune functions of astrocyte and microglia in the brain [133, 134]. More importantly,
we observed generalized up-regulation of immune response mechanisms within both the PFC and
NAc, suggesting that the neurotoxic response to chronic alcohol use is ubiquitous across cortical
and subcortical brain regions. Interestingly, in both brain regions, we further identified DEGs in
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the MT cluster (MT1HL1, MT1H, MT1X, MT1E, MT1G, MT1F, MT2A, and MT3). The MT
cluster is primarily responsible for maintaining the cellular homeostasis of zinc and copper while
also regulating oxidative stress [135]. Zinc is an essential catalytic cofactor for alcohol metabolism
via alcohol dehydrogenase [136]. Free or “chelated” zinc ions (Zn2+) are seen in abundance in the
brain, specifically at ionotropic glutamate receptors such as the NMDA receptor family. The
interaction between Zn2+ and NMDAR activity has shown to be an important contributor to
synaptic plasticity through regulating postsynaptic density assembly [47]. It is well understood that
chronic alcohol abuse leads to varying degrees of organ-wide zinc deficiency [138]; however, the
neurobiological consequences of how zinc deficiency in the brain contributes to AD
neuropathology is poorly understood. We believe this interaction between chronic alcohol abuse,
MT expression, zinc deficiency, and synaptic plasticity is an important avenue for future research
that should be explored.
In addition to identifying dysregulated immune response mechanisms, we validate recent
studies showing differential expression among signaling and neurodevelopmental processes within
AD cases [74–76, 117]. However, these processes are less conserved between cortical and
subcortical regions, likely due to the different neuronal composition and functional properties of
the PFC and NAc [139]. Interestingly, two NAc modules that primarily associate with cilium
assembly (NAcdarkorange) and cellular localization/morphogenesis (NAcpurple) show limited network
preservation within the PFC. There has been increasing evidence suggesting primary cilia aid in
facilitating extrasynaptic signaling during adult neurogenesis [140, 141], an important aspect of
addiction related extracellular membrane plasticity [142]. For example, GRP88, a g-protein
coupled receptor and primary cilia enriched gene [143], was linked to increased alcohol seeking
behaviors in knock out (KO) mice models [144], further reinforcing the importance of primary
cilia in AUD etiopathology. The cilium assembly genes enriched in NAcdarkorange, were shown to be
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associated with axonemal dynein assembly (DNAAF1, DNAI2, and DNALI1). A recent gene
expression study in adolescent rat hippocampus identified increased expression of two dynein
associated genes (dnai1 and dnah5) [145]. One explanation for increased expression of primary cilia
associated genes in the NAc relative to the PFC is related to potential discrepancies in adult
neurogenesis between subcortical vs cortical brain regions. It is well understood that most adult
neuronal stem cells originate in the ventricular–subventricular zones (V-SVZ) and migrate to
adjacent cortical and subcortical brain regions as neuroblasts to promote neurogenesis [146]. A
recent study showed increased adult neurogenesis of medium spiny neurons within the NAc and
that the migration and incorporation of new neurons was experience-based [147]. We believe that
the increased expression of genes that encode for the cilia assembly complex may reflective of
experience mediated neurogenesis of medium spiny neurons in NAc, except being driven by
chronic alcohol consumption instead of pain. These new neurons formed in response to alcohol
use may play an important role in the reward response deficits we often associate with addiction
and AUD [111].
Other interesting findings arise from our mRNA/miRNA interactions, e.g., when
correlating the MEs from mRNA and miRNA modules, we see distinct patterns between cases and
controls within both brain regions. Based on the known function of miRNAs in regulating the
expression of target mRNAs [148] we can infer these significant miRNA networks may serve as a
driving contributor for differential network expression between AD cases and controls. Specifically,
97% (35/36) of the hub genes from the NAcpurple module were significantly negatively correlated
with either mir-449a or mir-449b. Mir-449a/b have primarily been studied in the context of
spermatogenesis and cellular proliferation in cancer [149–151]. Based on the mRNA-miRNA
correlations, our study suggests that mir-449a/b cluster has additional functions related to cellular
proliferation in the brain. Among the genes correlated with mir-449a in the NAc, ELAVL4,
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DPYSL3, and KCNJ6 have shown significant associations with AD in other expression, and genetic
association studies [119, 152, 153], as well as being implicated in other SUDs [154–157].
In an attempt to understand the causal nature of the gene networks associated with AD, we
integrated genetic information via eQTL analysis. We were able to detect a significant number of
mRNA and miRNA cis-eQTLs from both brain regions. We selected highly significant eQTLs
(FCGR3A (Fc fragment of IgG receptor IIIa):rs12087446 and DNALI1 (dynein axonemal light
intermediate chain 1):rs12119598) based on FCGR3A and DNALI1’s role as network hubs to
highlight the interaction between AD case status and eQTL while also demonstrating brain regionspecific eQTL variation. FCGR3A is one of the low-affinity Fc receptor genes important for NK
cell-mediated antibody-dependent cytotoxicity [158] and a hub gene from our highly conserved
NAcgreenyellow and PFClightgreen modules. The consistent effect of rs12087446 on FCGR3A expression
between both brain regions suggests the genetic impact on immune response processes might also
be ubiquitous across the brain of chronic alcohol users. Differential FCGR3A expression was
recently shown to be associated with both alcohol preference and binge-like behaviors in the VTA
of rats [159]. In contrast, DNALI1, a hub gene in the cilium assembly enriched NAcdarkorange module,
is under the genetic control of specific eQTL only in NAc but not in PFC, suggesting that changes
to cilia organization due to alcohol abuse might be under different genetic control between the two
brain regions. We observed suggestive evidence for enrichment between our eQTLs and previously
published GWAS of alcohol or other addiction phenotypes, such as smoking. We believe this is
primarily due to three factors: 1) low statistical power within our sample to detect genetic signals
that would otherwise appear in large-scale GWAS studies, 2) our selective study design focusing
only on potentially clinically relevant eQTLs, and 3) the presence of variants with a lower minor
allele frequency (MAF) in the GWAS potentially not detectable in our dataset. We further
successfully replicated our eQTLs in the GTEx database for PFC, but not NAc. One possible
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explanation is that the increased number of DEG in the NAc relative to PFC with the fact GTEx
does not include AD diagnosed brains in their analyses [160] effectively limits our ability to
replicate GTEx eQTLs based on significant and potentially subtle non-significant expression
changes among AD cases.

3.5) CONCLUSION
The strength of this study lies in our ability to compare and contrast expression changes
between subjects with AD and controls within two different brain regions. We successfully
identified gene networks and biological processes from both brain regions that were validated by
previous AD studies as well implicated a novel biological process (cilia assembly) and gene family
(MT cluster) as potentially important for the development of AD. Our mRNA/miRNA interaction
analysis pinpointed mir-449a/b cluster as an important regulator of DEGs between AD cases and
controls. Finally, via our eQTL analysis, we provided evidence that mRNA and miRNA expression
differences between AD cases and controls might be under brain region specific genetic control.
While our sample size could be perceived as a limitation, we mitigated this by utilizing WGCNA
to aggregate DEGs into biologically relevant modules with single expression values, effectively
increasing our power to detect significant AD associations within a multivariate framework.
Additionally, to increase the power of our study, considering the more prevalent and heavier
drinking patterns in men, we assessed the molecular processes of alcohol drinking in male subjects
only. While we recognize the importance of comparing the molecular pathology of drinking
between the two sexes, we would like to highlight observations from genetic epidemiological studies
showing male and female subjects to have a similar genetic predisposition to alcohol abuse [161].
We further recognize that a number of our significant AD associated modules in PFC were also
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nominally correlated to neuropathology (p≤0.05). This is not entirely unexpected, given the known
neuropathological impact of chronic alcohol abuse [162]. Finally, while we understand that the
lower RINs from the PFC can be seen as confounding factor, studies have suggested that reliable
data can still be obtained from postmortem brain tissue even with suboptimal RNA quality .
However, our careful analytical design to adjust for the impact of RIN on gene expression
maintains the robustness of our results even in the presence of lower RINs.
Overall, the broader impact of our findings is the understanding that chronic alcohol
consumption can reinforce addiction behaviors through dysregulating different biological process
across various brain regions. This information could potentially lead to more focused therapies for
AUD by targeting important brain regions specific neurobiological pathways involved in the
development of alcohol addiction. While our results point to certain biological processes that
differentiate between the PFC and NAc, these findings require replication in an independent
postmortem brain samples spanning other cortical and subcortical brain regions. Additional
support for the postmortem brain findings presented here can also be obtained by studying ethanol
activity in animal models or neuronal cell cultures. Increased research within the methodological
framework of our study can help validate our findings and identify biological processes and genes
that play the most significant role in the development of AUD.
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CHAPTER 4
STUDY 2: Identifying a novel biological mechanism for
alcohol addiction associated with circRNA networks acting as
potential miRNA sponges in the nucleus accumbens of chronic
alcohol users.
4.1) INTRODUCTION
Alcohol is among the most readily available and commonly abused recreational drugs
worldwide with substantial socio-economic and public health implications [12]. The shift from
recreational alcohol use to problematic drinking, resulting in AUD is dependent upon genetic and
environmental factors [166]. AUD is moderately heritable (~49%) [110], however, the genetic
mechanisms underlying this heritability are poorly understood. While the alcohol dehydrogenase
cluster on chromosome 4 has been among the most consistently replicated genetic loci associated
with AUD [167], molecular studies from the MCL of human postmortem brains and animal
models have implicated additional AUD risk genes involved in neurosignalling, synaptogenesis,
and immune response [75, 168]. The limited overlap between molecular and genetic studies [169]
have hindered our understanding of the link between AUD associated genetic loci and gene
expression changes in the brain. Broadly, the human transcriptome can be divided into coding and
non-coding, with the non-coding transcriptome (represented by a large set of ncRNA species
characterized by their minimal or complete lack of protein-coding abilities and gene regulatory
functions [170, 171]) being a largely unexplored domain of the human genome with a potentially
substantial impact on the neuropathology of AUD. Among these, a particular class of ncRNA,
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termed circRNA have been implicated in the development of alcoholic hepatitis in mouse models
[107, 108].
CircRNA are abundantly and dynamically expressed throughout the mammalian central
nervous system (CNS) [103, 172]. They primarily arise from pre-mRNA splicing events in which
the 5’ and 3’ ends of introns or alternatively spliced exons are covalently linked to form closed loop
structures [173]. While several hypotheses have been proposed to explain the mechanisms by
which circRNAs regulate gene expression [174], a commonly accepted one, based on experimental
observations, is the miRNA-sponge hypothesis [175]. MiRNAs regulate gene expression mainly
through binding to the 3’ untranslated regions (UTRs) of their target genes, leading to translational
repression and mRNA degradation [176]. CircRNAs serve as competitive RNAs for miRNA by
competing with miRNA response elements (MREs) in the 3’UTRs of mRNA. This leads to miRNA
sequestration by circRNA and decreased miRNA-target interactions, effectively increasing gene
expression as a result [176].
With their varied spatio-temporal expression in the brain, circRNA were shown to be
implicated in the etiology of neurodegenerative and neuropsychiatric disorders [103, 178, 179].
To test whether these recent observations also extend to AD, we assessed the genome-wide
expression of circRNA, miRNA, and mRNA in NAc from subjects with AD followed by weighted
gene co-expression network (WGCNA) and bioinformatic and statistical analyses (Figure 11).
Finally, we applied an eQTL analysis to identify genetic elements affecting circRNA expression
and ability to interact with miRNA and mRNA. With this study, our main goals were to identify
the potential regulatory mechanisms by which circRNA affect the expression of risk AUD genes
and provide a methodological framework for exploring circRNA, miRNA, and mRNA
interactions in future postmortem brain studies. To the best of our knowledge, this is the first study
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to specifically examine the effect of circRNA on mRNA expression via miRNA sponge interactions
in NAc from chronic alcohol abusers.
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4.2) MATERIALS AND METHODS
4.2.1) Tissue Processing and RNA Extraction
Postmortem NAc from 42 AD cases and 42 controls was provided by the Australian Brain
Donor Programs of NSW TRC under the support of The University of Sydney, National Health
and Medical Research Council of Australia, Schizophrenia Research Institute, National Institute
of Alcohol Abuse and Alcoholism, and the New South Wales Department of Health [113]. As part
of a previous study [74], several criteria were used to exclude samples with (1) agonal state, (2)
substantial brain damage, (3) history of infectious disease and (4) post-mortem interval >48 hours
(Appendix I). Samples were further matched for RIN (mean=6.9, ±0.84), sex (all male), ethnicity
(100% Caucasian), brain pH, and PMI, to minimize covariates’ effect on expression, resulting in
18 matched case-control pairs (n=36). Total RNA from flash-frozen NAc was extracted and
purified via mirVANA-PARIS kit (Life Technologies, Carlsbad, CA) following the manufacturer’s
protocol. RNA integrity (RIN) and concentrations were assessed via Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc., Santa Clara, CA) and Quant-iT Broad Range RNA Assay kit (Life
Technologies) respectively.

4.2.1) Microarrays and Expression Normalization
Genome-wide circRNA, miRNA, and mRNA expression was assessed on three different
platforms: (1) Arraystar Human Circular RNA Array spanning 13,617 circRNA probes, (2)
Affymetrix GeneChip miRNA 3.0 Array spanning 1733 mature miRNAs, and (3) Affymetrix
GeneChip Human Genome U133A 2.0 array containing 22,214 probe sets spanning ~ 18,400
unique mRNAs. Raw expression data from each assay were background corrected, log2
transformed, and quantile normalized via Partek Genomics Suite v6.23 (PGS; Partek Inc., St.
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Louis, MO) and the limma package (version 4.0) in R. To exclude outliers that could impact
downstream analyses, 3 samples were removed from the circRNA normalized dataset, leaving 17
cases and 16 controls (n=33), and one sample was removed from both the miRNA and mRNA
normalized datasets, resulting in 17 cases and 18 controls (n=35). Since the mRNA and miRNA
expression arrays were validated previously [74], here we validate only the circRNA array by
assessing the expression of 3 randomly selected circRNA at the Arraystar facilities via quantitative
PCR (qPCR). The assessed genes showed a high mean correlation (Kendall tau r=0.87
(SD±0.021)) between the two platforms (Figure 12).

Figure 12: Validation of circRNA microarray via qPCR. The validity of the Arraystar Human Circular RNA
Array was assessed by performing qPCR on 3 randomly selected circRNA. Overall, we identify a high
mean correlation (Kendall tau r=0.87 (SD±0.021)) between the two platforms.

4.2.3) Identifying Differential Transcript Expression
We assessed the relationship between transcript expression and AD case status via two
different regression analysis in RStudio (ver. 1.2.1335). Differentially expressed miRNA and
mRNA were identified via a bidirectional stepwise regression elsewhere [168] using the Stats
package (v.3.6.1) adjusting for demographic and postmortem covariates. Differential circRNA
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expression was assessed via robust linear regression via the MASS package (v.7.351.5) with smoking
and RIN included as covariates in the model [180] as these have been shown to have a greater
impact on circRNA expression [181, 182], compared to other demographic and postmortem
covariates [183].

4.2.4) Weighted Gene Co-expressed Network Analysis
The network analysis was performed on the nominally significant differentially expressed
circRNAs (p≤0.05) using the WGCNA package in RStudio (v.1.69). Our selection criteria to
include nominally significant genes were based on retaining genes with (i) smaller effect sizes, albeit
true positive signals, (ii) exclude genes not likely associated with AD, and (iii) provide a sufficient
number of genes for the network analysis. In the WGCNA, our similarity matrix was raised to a
power (b = 8) to approximate the scale-free topography of the adjacency matrix, in which stronger
correlations are emphasized over weaker ones. Transcript interconnectedness was determined
from the calculated topological overlay measure (TOM). The default, unsupervised hierarchical
clustering method was used to partition modules at specified dendrogram branch cut sites using
the Dynamic Tree Cut method. Highly correlated modules were then merged based on minimum
merge height of r2 = .8 and minimum module size of 15. We used M1-M10 to categorically label
co-expressed networks and the sum of relative expression within each module is represented as a
MEs and used for downstream phenotypic analysis. MEs were then correlated to AD case-status
and available demographic/biological covariates. To further validate the gene networks associated
with AD in WGCNA, we also performed a bootstrap based resampling of 100 iterations with
replacement (Figure 13).
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Figure 13: CircRNA robust WGCNA dendrogram module clustering. To ensure network robustness
and minimize the potential effect of outlier samples on network structure, we used the robust
‘bootstrapped’ version of WGCNA as described in Figure 4.
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4.2.5) CircRNA Hub Gene Prioritization
CircRNA hubs were identified from the absolute value of the Pearson’s correlation
coefficient between MEs and individual gene expression. This value of intramodular connectedness
denoted as module MM was used to define circRNA hubs as transcripts significantly correlated to
AD (p≤0.05) and a MM≥0.70 within the significant AD modules.

4.2.6) Correlations Analysis between circRNA, miRNA, and mRNA
We used only subjects with complete data across all three expression platforms (i.e., 17 AD
cases and 15 controls). The circRNA:mRNA:mRNA correlations were based on Pearson’s product
moment generated in the miRLAB package (ver. 1.14.3) in RStudio. All significant negative
circRNA:miRNA, negative miRNA:mRNA, and positive circRNA:mRNA correlations,
respectively, were extracted at a FDR of 10% and retained for follow up analyses.

4.2.7) Computational Prediction of circRNA:miRNA Interactions
The circRNA-miRNA correlations were supplemented with computational predictions
using STarMir in the Sfold application suite (http://sfold.wadsworth.org/cgi-bin/index.pl) [184].
STarMir calculates probability scores for binding predictions of shared seed sequences between
circRNA and miRNA [185] based on logistic regression models developed from crosslinking
immunoprecipitation (CLIP) studies [186]. Based on STarMir's recommendations, probability
scores ≥0.50 were considered significant [184].

4.2.8) Prediction of miRNA:mRNA Target Interactions

51

Similarly, the miRNA:mRNA correlations were complemented with miRNA target
predictions from the multiMiR package (v.1.6.0) in Rstudio. MultiMiR is a curated database of
miRNA:mRNA target predictions which integrates both computational prediction algorithms
(DIANA-microT-CDS, ElMMo, MicroCosm, miRanda, miRDB, PicTar, PITA, and TargetScan)
and experimentally validated miRNA-target interactions (miRecords, miRTarBase, and TarBase)
[187].

4.2.9) Moderation Analysis
The test for moderation, i.e., whether miRNA expression moderates the relationship
between circRNA and target mRNAs, we utilized the Stats package in RStudio. The following
linear regression model was used to test the impact the circRNA x miRNA interaction term on
mRNA:

! = #0 + #1 + #2 + #3 + #4 + #5 + #4 ∗ #5 + -. In this model ! is mRNA

expression, #1 is AD diagnosis, #2 is RIN, #3 is smoking history, #4 is circRNA expression, #5 is
miRNA expression, #4 ∗ #5 is our circRNA-miRNA interaction of interest, and - is the error
term. Significance was based on an FDR ≤0.10 threshold.

4.2.10) Gene-set Enrichment Analyses
We performed a GO biological processes gene-set enrichment via ShinyGO (v.0.61) at each
stage in our analyses on mRNAs participating in significant circRNA:miRNA:mRNA interactions.
ShinyGo utilizes a hypergeometric distribution to determine significant enrichment at a FDR
≤0.10 [188].
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4.2.11) CircRNA eQTL Analysis and Enrichment in GWAS of
Substance Abuse
The postmortem sample was genotyped as part of a larger GWAS study [74].
Monomorphic SNPs and those with excessive missingness (>20%) were filtered out. Only local,
cis-eQTLs within 500kb of each circRNA hub’s start/stop position were mapped, and variants in
LD (R2≥0.7) were subsequently pruned via Plink v1.9 [189]. We utilized the MatrixEQTL package
(ver. 2.3) in RStudio using a linear regression model adjusting for relevant covariates to detect ciseQTL. The overlap (i.e., enrichment) was tested between our eQTLs and recent GWAS of
substance abuse, including alcohol and smoking, using two mutually complementing tests (Cauchy
Combination and Simes [130, 190]) adjusting for multiple testing and LD (R2 ≥0.50). For more
details, see (Appendix II).

4.3) RESULTS
4.3.1) CircRNA are organized in networks associated with AD.
At the nominal p≤0.05, our gene expression analysis revealed 542 differentially expressed
circRNAs between AD cases and controls (Figure 14A), with none of them achieving significance
at FDR≤0.10. The nominally significant circRNAs clustered into 9 modules significantly
correlated to AD (Bonferroni adj. p≤0.05) (Figure 14B), of which M1, M2, M4, and M5 were
positively correlated, whereas M6-M10 were negatively correlated to AD status. From these
modules, we identified 137 hub genes, which were selected for downstream statistical and
bioinformatic analyses against mRNA (n=3,575) and miRNA (n=264) significantly associated with
AD at a FDR≤0.10 as a part of a previous study on the same subjects (Figure 14A) [169]. See
Appendix V for hub circRNA annotations, regression coefficients, and MM.
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Figure 14: Differentially expressed transcripts and circRNA WGCNA results. A) Volcano-plots
describing the relationship between regression estimates and -log10(p) for each transcript level in our
analysis (circRNA, miRNA, and mRNA). Dashed lines correspond with the significance threshold of
p≤0.05 and FDR≤0.10. B) WGCNA module clustering dendrogram from our nominally AD significant
(p≤0.05) circRNA transcripts C) Heat plot comparing the correlation (Pearson’s) of our identified circRNA
module MEs to AD diagnosis and all other available covariates. In respect to AD diagnosis, the top value
represents the correlation coefficient, and the bottom value represents uncorrected p-values. For
covariates: * = p ≤0.05 and ** = p≤0.005.
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4.3.2) CircRNA, miRNA and mRNA show complex interaction
patterns associated with AD.
We tested the circRNA ability to interact with miRNA and thus indirectly affect the
miRNA target’s expression in a disease dependent manner. Assuming circRNA act as miRNA
sponges to impact mRNA expression, we posit that the most relevant downstream biological
interactions will be represented by negative miRNA:mRNA and positive circRNA:mRNA
correlations. Thus, we first performed three independent correlation analyses (circRNA:miRNA,
miRNA:mRNA, and circRNA:mRNA) followed by tests to identify the intersection between these
interactions at FDR of 10%. In the circRNA:miRNA (circRNA n=137; miRNA n=264) analysis,
we identified 48 significant negative circRNA:miRNA correlations. The miRNA:mRNA (miRNA
n=264; mRNA n=3,575) analysis revealed 46,501 significant negative correlations. Finally, the
circRNA:mRNA (circRNA n=137; mRNA n=3,575) analysis revealed 2,221 significant positive
correlations. From the intersection of these analyses, we identified a total of 2,480 overlapping
correlations, which were then used in all subsequent follow-up analyses.

4.3.3) Binding

predictions

supplement

intersecting

circRNA,

miRNA, and mRNA correlations.
To reinforce and complement our correlation analyses, the 2,480 overlapping
circRNA:miRNA:mRNA correlations were further screened computationally to identify predicted
circRNA:miRNA and miRNA:mRNA interacting pairs. Based on the STarMir’s algorithm, no
circRNA:miRNA binding predictions with a score greater than our significance threshold (logit
probability≥0.50) were detected when circRNA:miRNA correlations were considered in isolation.
However, by expanding the circRNA:miRNA binding predictions to include circRNA:miRNA
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pairs correlated to the same mRNA, we identified 365 circRNA:miRNA:mRNA trios with
intersecting negative miRNA:mRNA correlations, positive circRNA:mRNA correlations, and
predicted circRNA:miRNA binding. We further narrow down these 365 interactions via a
selection of the best miRNA:mRNA target predictions to identify the most robust 47 circRNA,
miRNA, and mRNA participating in a three-way interaction.

4.3.4) Moderation analysis reveals circRNA x miRNA interactions
impact mRNA expression.
The impact of miRNA sequestration on mRNA expression from these 47 circRNA,
miRNA, and mRNA was formally tested in a linear regression model adjusting for AD status and
controlling for covariate effects (RIN and smoking history). In the model, the miRNA sequestration
by circRNA was assessed by introducing a (circRNA x miRNA) interaction term. At FDR≤0.10,
we identified 23 interactions that show significant moderation effect on mRNA expression (Table
1). Interestingly, among these 23 interactions, circRNA-406702:miR-1200 stood out by affecting

the expression of the largest set of mRNA (n=17) four of which (HRAS, PRKCB, HOMER1, and
PCLO) are highlighted in Figure 15. For full moderation regression coefficients, see Appendix VI.
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circRNA:miRNA:mRNA Interactions

miRNA:mRNA Cor

circRNA:mRNA Cor

circRNA:miRNA Binding

circRNA

miRNA

mRNA

Coef

FDR

Coef

FDR

Logit Prob

Seed

circRNA-406742

hsa-miR-1200

ACTR2

-0.4251

0.0909

0.5044

0.0998

0.6955

circRNA-406742

hsa-miR-1200

ASTN1

-0.5425

0.0260

0.5057

0.0987

circRNA-406742

hsa-miR-1200

ATP2B2

-0.5330

0.0293

0.6079

circRNA-406742

hsa-miR-1200

E2F3

-0.5165

0.0361

circRNA-406742

hsa-miR-1200

HOMER1

-0.5717

circRNA-406742

hsa-miR-1200

HRAS

circRNA-406742

hsa-miR-1200

circRNA-406742

miRNA:mRNA target Predic
Predicted

Circ X mi Interaction

Experimental

Estimate

FDR

offset-6mer

X

0.8127

0.0898

0.6955

offset-6mer

X

2.0620

0.0070

0.0440

0.6955

offset-6mer

X

2.5879

0.0077

0.5530

0.0708

0.6955

offset-6mer

X

0.9043

0.0913

0.0169

0.6755

0.0237

0.6955

offset-6mer

X

1.7868

0.0077

-0.4523

0.0715

0.6014

0.0470

0.6955

offset-6mer

X

1.8261

0.0077

IMP4

-0.5091

0.0394

0.5483

0.0739

0.6955

offset-6mer

1.5305

0.0008

hsa-miR-1200

IPCEF1

-0.5550

0.0218

0.5356

0.0801

0.6955

offset-6mer

X

2.0946

0.0086

circRNA-406742

hsa-miR-1200

LDB2

-0.4212

0.0939

0.6082

0.0440

0.6955

offset-6mer

X

3.5155

0.0086

circRNA-406742

hsa-miR-1200

NDST3

-0.5663

0.0185

0.5400

0.0779

0.6955

offset-6mer

X

2.7353

0.0096

circRNA-406742

hsa-miR-1200

OSBPL8

-0.5532

0.0223

0.5434

0.0761

0.6955

offset-6mer

X

1.9161

0.0077

circRNA-406742

hsa-miR-1200

PCLO

-0.5141

0.0371

0.5592

0.0677

0.6955

offset-6mer

X

2.5603

0.0070

circRNA-406742

hsa-miR-1200

PRKCB

-0.5650

0.0188

0.5873

0.0535

0.6955

offset-6mer

X

5.3517

0.0009

circRNA-406742

hsa-miR-1200

RAB11FIP2

-0.5455

0.0250

0.5758

0.0583

0.6955

offset-6mer

X

0.9061

0.0104

circRNA-406742

hsa-miR-1200

RANBP2

-0.4977

0.0450

0.5858

0.0543

0.6955

offset-6mer

X

0.8803

0.0368

circRNA-406742

hsa-miR-1200

RFC2

-0.4256

0.0906

0.5162

0.0915

0.6955

offset-6mer

X

0.8356

0.0380

circRNA-406742

hsa-miR-1200

SSX2IP

-0.7589

0.0001

0.5269

0.0847

0.6955

offset-6mer

X

2.0238

0.0009

circRNA-000390

hsa-miR-361-5p

NEK7

-0.5016

0.0430

0.6356

0.0342

0.7444

offset-6mer

X

X

2.2585

0.0898

circRNA-065645

hsa-miR-571

NR3C1

-0.4644

0.0639

0.5547

0.0697

0.7044

offset-6mer

X

-1.5579

0.0550

circRNA-405170

hsa-miR-4310

CELF1

-0.4440

0.0773

0.5324

0.0812

0.7029

7mer-m8

X

X

0.6517

0.0898

circRNA-101134

hsa-miR-665

MLEC

-0.5167

0.0361

0.5433

0.0762

0.6796

6mer

X

-0.6227

0.0134

circRNA-001072

hsa-miR-3187-3p

GPD2

-0.5295

0.0307

0.5681

0.0622

0.6087

7mer-A1

X

-0.7690

0.0380

X

Table 2: Top circRNA:miRNA:mRNA interactions. Significant circRNA:miRNA:mRNA interactions that survive all of our bioinformatic and
statistical tests (i.e. negative miRNA:mRNA correlation, positive circRNA:mRNA correlation, circRNA:miRNA predicted binding, miRNA:mRNA
target prediction, and moderation regression).
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Figure 15: CircRNA-406702:miR-1200 interacting trans-synaptic signaling associated genes. A)
Boxplot showing relative expression differences between AD cases and controls for miR-1200. B)
Diagram of predicted binding loci between circRNA-406702 and miR-1200. C) Boxplot showing relative
expression differences between AD cases and controls for circRNA-406702. D) Correlation plots
displaying the significant negative relationship between miR-1200 and interacting trans-synaptic
signaling associated genes (HRAS r2=-0.45; PRKCB r2=-0.57; HOMER1 r2=-0.57; PCLO r2=-0.51) E)
Correlation plot displaying significant positive relationship between circRNA-406702 and select genes
HRAS r2=0.61; PRKCB r2=0.59; HOMER1 r2= 0.68; PCLO r2=0.56). F) Boxplots for differential mRNA
expression between AD cases and controls and diagram of miRNA predicted binding to the 3’UTR of
target genes.
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4.3.5) CircRNA interact with genes associated with neuronal
function.
At each stage of our analyses, we consistently identified significant enrichment (FDR≤0.10)
of genes involved in cellular localization, synaptic transmission, neural development, and response
to organic stimuli gene-sets (Figure 16). The 23 circRNA:miRNA:mRNA interactions also
revealed significant enrichment (FDR≤0.10) for GO biological processes associated with regulation
of DNA metabolism, anatomical structure homeostasis, regulation of biosynthesis, dendritic spine
organization, and anterograde trans-synaptic signaling.

4.3.6) Genetic variants potentially impact circRNA expression.
Our eQTL analysis revealed 3 significant circRNA-eQTLs at an FDR≤0.10 (Figure 17A).
When we repeated the eQTL analysis taking into consideration the interaction (AD x genotype)
term, we detect 7 additional significant eQTLs (FDR≤0.10), which were associated with one
circRNA (circRNA-080252). After expanding our eQTL analysis to incorporate results at a more
relaxed significance threshold, (unadj. p≤0.002), we identified additional 96 eQTLs that were used
in the downstream enrichment analysis. Among these, we identified multiple circRNA that
participated in significant circRNA:miRNA:mRNA interactions at various stages in our multi-step
analyses (Figure 17B/C). For full eQTL results, Appendix VII.
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Figure 17: Significant circRNA cis-eQTLs. A) eQTLs that survive FDR ≤0.10 significance threshold. B)
eQTLs from circRNA:miRNA:mRNA trios with negatively correlated miRNA:mRNA, positively correlated
miRNA:mRNA, predicted circRNA:miRNA binding, and miRNA:mRNA predicted interactions. C) eQTLs for
circRNA that participate in circRNA:miRNA:mRNA interactions that survive all our bioinformatics and
statistical tests.
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4.3.7) CircRNA associated SNPs are enriched within AUD and
smoking GWAS.
We employed the Cauchy Combination (CC) and Simes [130, 190] tests to detect eQTLs
(n=96) and SNPs in LD with them (r2≥0.50; n=1,558) that were enriched among the significant
(p≤5E-4) loci from recent GWAS of AUD and smoking [128] and Psychiatric Genetics
Consortium (PGC) AUD GWAS [29]). Adjusting for multiple testing and background enrichment,
we observed significant enrichment for our eQTLs in GSCAN cigarettes per day, GSCAN
smoking initiation and PGC-AUD European ancestry (Table 3).
Study
GSCAN drinks per week
GSCAN smoking initiation
PGC AUD Europeans
COGA+Irish AUD meta-analysis
GSCAN cigarettes per day
GSCAN smoking cessation

CC p-value
1
0.024*
0.034*
0.044*
1.41E-05**
1

Simes p-value
0.2139
0.053^
0.058^
0.086^
2.74E-05**
0.564

Table 3: CircRNA hub eQTL enrichment within addiction GWAS. We observe significant enrichment
when comparing eQTLs associated with circRNA hubs from our analysis against recent GWAS of AUD
and smoking.^= p≤0.10, * = p≤0.05, and ** = p≤0.005.

4.4) DISCUSSION
In recent years, studies on AUD have attempted to identify the underlying molecular
mechanisms for the development of problematic and addictive drinking behaviors. Much of the
functional neurobiological work has been performed in animal models [192], whereas large-scale
GWAS have attempted to identify heritable genetic variants associated with AUD and other
addictive behaviors [192, 193]. The translation of findings from human genetic studies to
functional animal studies, however, has been limited [194]. This is most likely due to the complex
non-linear relationships between environmental and genetic factors in humans that are difficult to
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recapitulate in animal models of AD. Thus, to address this interaction between environmental and
genetic factors we decided to explore the transcriptome (mRNA, miRNA, and circRNA) as the
functional endophenotype between genetic variation and molecular processes in human
postmortem brain tissue from subjects with AD.
Our group has identified miRNA and mRNA networks associated with AD, assigned
biological function to these networks, tested their preservation between cortical and subcortical
brain regions and assessed the impact of genetic variation on specific network hub expression [74,
168]. Here, we were interested in complementing these earlier studies to determine the impact of
circRNA on the molecular processes underlying the neuropathology of AUD, within the
framework of the miRNA sponge hypothesis. Network approaches have the added benefit of
aggregating transcripts with small effect sizes into clusters that, when analyzed as a single
expression unit, increase power to detect significant results [120]. Additionally, we limit our
downstream analyses to the identified circRNA hubs based on their high intramodular connectivity
and predicted role as drivers of expression changes for entire modules, effectively increasing their
biological relevance to AD [70].
Our study relied upon a series of experimental, statistical and bioinformatics tests to narrow
down well over a billion possible interactions between circRNA, miRNA, and mRNA to highly
specific three-way interactions within the miRNA sponge hypothesis that survive several layers of
correction for multiple testing. Among our most significant circRNA:miRNA interacting pairs,
(i.e., circRNA-406702:miR-1200), we observed a unique set of genes negatively correlated with
miR-1200 and positively correlated with circRNA-406702. Some of these (such as HRAS, PRKCB,
HOMER1, PCLO, ASTN1, and ATP2B2) are enriched within gene-sets associated with synaptic
transmission/development, highlighting their potential importance to the neuropathology of AD
[195]. HRAS, a small GTP-binding protein, interacts with downstream PI3K, AKT, and
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mTORC1 as part of a neurosignalling pathway (“Go” pathway) believed to be important for
promoting neuroadaptations associated with excessive alcohol consumption and relapse [196].
This is supported by studies showing HRAS expression is increased among mice strains consuming
alcohol in high quantities [197], as well as in the NAc of rats with an extended history of excessive
consumption followed by periods of abstinence [198]. However, in contrast to the animal-based
studies, in our sample, we observed decreased HRAS expression in AD subjects. A possible
explanation would be that the ligand-gated ion channels mediating HRAS activity become
desensitized due to chronic receptor activation after years of alcohol abuse which cannot be easily
replicated in animal models [199, 200]. PRKCB (protein kinase C beta), another gene implicated
in our study, is an isoform of the protein kinase C (PKC) family. This set of proteins is shown to be
essential for the development of AD through their interaction with CREB-BDNF neurosignalling
pathway, which was reported to be associated with synaptic plasticity . More importantly, genetic
variants nearby PRKCB have been significantly associated with comorbid bipolar disorder, SUD
[204], and alcohol cue‐elicited brain activation [203].
Among the other genes interacting with circRNA-406702:miR-1200 are HOMER1 and
PCLO, which encode for proteins playing an important role at the synapse. HOMER1 encodes for
one of the Homer scaffolding proteins (Homer1/2), which link metabotropic glutamate receptors
(mGlu1-5) to the postsynaptic density [205]. Both HOMER1 and one of the mGlu receptor,
GRM5, have been consistently implicated as potential therapeutic targets for the treatment of AD
due to their role in regulating alcohol facilitated neuroplasticity [81, 206]. Additionally, it has been
shown that a polymorphism (rs7713917) in the regulatory region of HOMER1 can help predict
increased alcohol consumption in adolescents years later [207]. PCLO codes for the Piccolo protein,
a scaffolding protein at the active zone of the presynaptic cytomatrix, an area where
neurotransmitters are released [208]. Intronic SNPs within the PCLO gene have been one of the
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most studied genetic variants associated with major depressive disorder [209]. Functional studies
have suggested that these polymorphisms may play an active role in emotional memory processing
[210, 211] and previous research has indicated that deficits in emotional processing is a hallmark
of AD [212]. This deficit then may lead to enhanced emotional reactivity to positive and negative
stimuli during periods of drinking and periods of withdrawal, effectively reinforcing continued
alcohol abuse [213, 214]. Importantly, PLCO, along with HOMER1 have both been implicated as
differentially expressed in multiple gene expression studies of AD [215–219]. Finally, ASTN1
(Astrotactin 1) is a gene that codes for a protein receptor important for glial-guided neuron
migration [220]. In the context of AD, a family-based linkage study has shown ASTN1 is
significantly associated with AD in multiplex families. Overall, the results from our study provide
further support for research suggesting circRNA play an important, yet still underexplored, role in
neuronal function [221].
Some of the miRNAs implicated at various steps in our circRNA analysis, while not all of
them directly associated with AD, show significant associations with alcoholic liver disease, brain
function, and neuropsychiatric disorders. Among the several miRNA identified from our
significant circRNA:miRNA interactions, miR-665 is significantly upregulated in the PFC of
alcoholics [96], and miR-361-5p shows increased expression in the PFC of early stage AD mouse
models [222]. The maternal expression of another miRNA from our study (miR-3119) was shown
to increase following alcohol consumption during pregnancy [223]. Two other miRNAs (miR1200, and miR-3187-3p) have been implicated in various neurobiological processes relevant to AD
etiology. Of these, miR-1200 has been predicted to regulate neuronal connexins 36, 45, and 57 in
humans, mice and rats [224]. Connexins (Cx) are essential for gap junction function at electrical
synapses, with Cx36 shown to be associated with various rewarding effects of alcohol intoxication
in knock-out (KO) mice [225]. Another report has suggested miR-3187-3p expression changes
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modify the neuronal cell response to oxidative stress [226]. Increased oxidative stress is a wellknown consequence of alcohol’s neurotoxic effects in the brain [227] with multiple studies from
our group and others identifying increased expression of immune and stress response genes in the
postmortem brains of chronic alcohol users [77, 168, 228]. Finally, miR-571 has shown to be an
important biomarker for alcohol related liver disease [229]. We further show that miR-571
interacts significantly with NR3C1, a highly pleiotropic glucocorticoid receptor, necessary for stress
response and reported to be significantly associated with AD [230, 231].
In respect to our cis-eQTL analysis, we identify genetic variants that impact the expression
of our circRNA hubs. While no specific polymorphisms at the genome-wide significance level
(p≤5E-8) in GWAS of AUD were replicated among our eQTLs, we observed significant
enrichment at a lower significance threshold (p≤5e-4) using two separate genomic enrichment tests
using recent GWAS of AUD and smoking [29, 128]. Possible explanations for this observation are
the limited power of our postmortem brain sample and GWAS of AUD that are still underpowered
[232]. However, most likely with increased postmortem brain sample sizes [233] and deepphenotyping of subjects with chronic alcohol abuse [234], we may begin to see a meaningful
overlap between the results from these two methods. Nevertheless, the importance of identifying
eQTL enrichment among GWAS signals from our eQTL analysis is two-fold: first, help validate
the clinical relevance of these large association studies by providing a functional explanation for
AUD associated GWAS signals, and second reinforce such identified eQTLs and SNPs in LD as
likely candidates for future, more targeted, follow up analyses. Our study also highlights a
potentially novel neurobiological mechanism of alcohol addiction by demonstrating that alcohol
abuse may impact the expression of known AD risk genes through altering circRNA expression
and circRNA’s ability to act as miRNA sponges. Our circRNA eQTL study further suggests that
we must be careful when interpreting GWAS signals given that genetic variants impacting the
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expression of proximal circRNA can alter the expression of distal genes through the epistatic
interaction between circRNA and miRNA.
Our study does also have a few limitations. First, it is possible that by focusing solely on the
circRNA and miRNA interactions, we may have overlooked other molecular mechanisms (i.e.
epigenetic factors) that potentially can also affect the functions of risk AD loci. Second, while the
use of male subjects only can be perceived as a limitation, this was a deliberate choice in order to
increase our statistical power by removing sex-based variability. Genetic epidemiological studies
have shown that male and female subjects have a similar genetic predisposition with respect to
alcohol abuse [161].
In summary, to the best of our knowledge, ours is the first to specifically investigate the
effect of circRNA and miRNA interactions on gene expression in NAc from subjects with AD. We
are confident that this pilot study opens the door for future studies that will corroborate our findings
by experimentally validating these results and further exploring them in the context of increased
and more diverse postmortem brain databases. Moreover, we believe that our study will be the
steppingstone on which future studies will expand on our integrative analytical approach to
incorporate other brain regions and psychiatric phenotypes.
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CHAPTER 5
CONCLUSION
5.1) SUMMARY
The purpose of this dissertation was to identify biological processes associated with AUD
via comparative transcriptomic analyses from the postmortem brains of chronic alcohol abusers.
We also explored the regulatory mechanisms for significant differential expression through
integrating ncRNA interactions and genotypic information. Overall, we identified DEG networks
associated with AD that displayed either high or low levels of network preservation between areas
of the MCL, while also providing a novel mechanism for the regulation of AUD associated genes
in the form of circRNA:miRNA:mRNA interactions.
In Study 1, we validate previous research that shows immune/stress response upregulation
is associated with AD, which is believed to be the neurotoxic consequence of chronic ethanol
exposure in the brain. More specifically, we implicate the differentially expressed MT cluster as an
oxidative stress response mechanism that can impact synaptic plasticity through regulating
extracellular Zn2+, an important cofactor for neurotransmission [137, 138, 235]. When we
examine biological processes that show little to no conservation between brain regions, we observe
that genes associated with cilia based cell projection appear to be disproportionately dysregulated
within the NAc of chronic alcohol abusers. This could be representative of experience-based adult
neurogenesis of medium spiny neurons facilitated by alcohol consumption and intoxication [147].
These findings set the framework for looking at biological processes that underlie specific addiction
reinforcing behaviors based on functional specialization and the differences in gene dysregulation
between cortical and subcortical brain regions. In a broad sense, we hope investigating specific
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brain regions within the context of AUD can inform more focused therapeutic interventions to
target neurobiological processes that impact addiction in a brain-region specific manner.
Study 2 serves as a pilot study for assessing circRNA expression changes in the postmortem
brain of chronic alcohol abusers while also providing the analytical framework for investigating
miRNA sponge interactions in silico. Our integrative statistical and bioinformatic approach which
included correlation, ncRNA target prediction, and moderation regression, allowed us to identify
significant circRNA:miRNA:mRNA interactions associated with AD. More importantly, these
findings revealed significant circRNA interacting genes that are associated with trans-synaptic
signaling and neuroplasticity, meaningful biological processes in respect to the development of
addictive behaviors [195]. Additionally, we identified significant cis-eQTLs for differentially
expressed circRNA that also show overlap with recent GWAS of AUD and smoking. By
highlighting GWAS enriched SNPs associated with circRNA that participate in significant miRNA
sponge interactions, we provide a functional explanation for previous GWAS where interpretation
has been notoriously challenging [236, 237]. These findings also highlight additional issues when
interpreting GWAS. Significant hits are often inherently associated with the genes at proximal loci
or the genes in which they are embedded [238]. When we consider circRNA, there is the possibility
a local SNP may impact the expression of an intronic/exonic circRNA rather than the expression
of its host gene, leading to functional expression changes at distal loci due to
circRNA:miRNA:mRNA interactions.
The results from these two studies highlight the utility of postmortem brains and
transcriptomic profiling for the study of AUD and other SUDs. We reveal novel neurobiological
processes of particular relevance to the development of AUD within the framework of the cycle of
addiction. We also provide the first account of circRNA as important molecular moderators for
expression changes of previously identified AUD risk genes through their role as miRNA sponges.
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5.2) LIMITATIONS
Like most research, this dissertation is not without its own set of limitations. Most notably
is our decreased statistical power to detect significant results due to limited samples sizes. To
combat this, we utilized robust statistical analyses in which cases and controls were matched for
biological and technical covariates in an effort to control for potential confounds. In most cases we
still identified substantial effect sizes for DEG that can be deemed significant even after FDR
correction. This is unfortunately a limitation that is shared across all postmortem brain studies
given the limited availability of useable tissue [180]. As brain banks worldwide continue to expand
their repositories, the scientific impact of postmortem brain studies will continue to increase as
sample sizes increase. Additionally, in an effort to limit the effect of confounding factors, we made
the conscious decision to only utilize male tissue. Therefore, it is important to acknowledge that
the findings presented here can only be interpreted within the context of people assigned male at
birth. Finally, as mentioned in Chapter 1, we have to be careful when making causal inferences
from our results, given that cases represent chronic alcohol abusers diagnosed with severe AD. For
this reason, it is difficult to determine if these results are indicative of biological processes
dysregulated in response to chronic alcohol consumption or if they represent predictive risk factors
that cause AUD. Like other neuropsychiatric disorders, AD risk is determined based on a
combination of environmental and genetic factors [161, 166]. Interestingly for AUD, the act of
consuming alcohol serves as an environmental risk factor in itself, creating a feedback loop for
continued abuse due to positive or negative reinforcement and conditioning during periods of
intoxication followed by withdrawal. So, while we acknowledge that determining the causal
relationship between our data and the development of AUD is limited, we do reveal biological
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process and gene regulatory mechanisms that can still serve as useful biomarkers for predicting and
potentially treating AUD.

5.3) FUTURE DIRECTION
The research presented in this dissertation provides the framework for future molecular
genetic studies of AUD and other neuropsychiatric disorders. Most notably is the need to replicate
and validate these findings in both expanded postmortem brain studies and experimental studies
using proven animal and cell models as proxies for human brain tissue. Ideally, future research can
utilize the computational framework presented to investigate DEG networks associated with AUD
that are shared or unique to other brain regions believed important for addiction (i.e. the VTA,
hippocampus, and amygdala). Additionally, we believe our study design for both comparing the
transcriptomic profiles between different brain regions and assessing disease associated
circRNA:miRNA:mRNA interactions can be easily translated to the study of other
neuropsychiatric and neurodegenerative disorders. Experimental validation of Study 2 results will
be key for determining if our in silico predictions of circRNA acting as miRNA sponges accurately
represent what is occurring in vivo. One possibility would be performing a luciferase reporter
experiment [239] on a circRNA:miRNA:mRNA trio to assess the ability of miRNA to attenuate
the expression of the target gene in the presence of circRNA expressed in different quantities.
When the miRNA is overexpressed, it is expected to observe decreased mRNA expression, but
when circRNA is spiked-in, the effect of miRNA on mRNA expression will be weakened as miRNA
preferentially interacts with the overexpressed circRNA instead. Additionally, it would be possible
to perform knockout and knockdown experiments on animal models in which the expression of
miRNA and circRNA are manipulated to explore the mediating effect of circRNA:miRNA
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interactions on mRNA expression. In a broader sense, the findings presented here and in follow
up studies should be explored within the context of identifying targeted therapeutics for ethanol
sensitive biological processes to help prevent and protect against the development of severe
debilitating AUD.
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APPENDICES
Appendix I: Sample Demographics
ID

Diagnosis

Age

NAc RIN

PFC RIN

13

Alcohol

61

6.9

3.6

18

Control

44

6.9

3.7

20

Control

62

8.1

24

Alcohol

56

25

Control

63

26

Alcohol

27

Control

30

Weight (g)

pH

PMI

Hemisphere

Neuro.

Hepat.

Tox

Smoking

1340

6.93

21

0

0

1

2

1

1220

6.6

50

0

0

0

9

2

3.4

1480

6.56

37.5

1

0

1

9

9

6.4

2.1

1284

6.51

45

0

0

1

1

9

7.3

5.2

1570

6.94

24

1

0

1

2

1

42

6.4

5.8

1400

6.5

41

0

1

1

2

0

46

7

1.4

1490

6.65

25

1

0

1

0

9

Control

56

7.1

3.8

1510

6.76

37

1

0

1

9

1

33

Alcohol

52

6

2.8

1380

6.78

45.5

0

1

1

0

1

35

Control

43

8.3

2.9

1500

6.43

13

1

0

0

0

2

40

Alcohol

59

6.7

2.6

1520

6.57

24

0

0

1

0

0

42

Alcohol

56

8.2

2.5

1230

6.52

22

0

1

1

0

1

43

Alcohol

54

7.8

7.8

1340

6.41

17

0

0

1

1

1

45

Alcohol

46

8

2.9

1200

6.51

24

1

0

1

1

9

46

Alcohol

39

7.6

2.8

1360

6.56

24

0

0

1

9

1

48

Alcohol

73

8.5

5

1300

6.3

24

0

1

1

1

0

51

Control

56

7.8

7.2

1635

6.53

24

1

0

9

9

1

54

Control

50

7.3

7.9

1500

6.26

19

0

0

1

0

2

56

Alcohol

63

5.5

4.3

1616

6.21

25.5

1

1

1

0

1

57

Alcohol

50

6.2

3.6

1420

6.59

24

0

1

1

1

1

60

Alcohol

50

6.3

6.6

1520

6.3

17

0

1

1

9

9

61

Alcohol

51

6.4

2.2

1460

6.35

46

0

1

1

9

1

62

Alcohol

64

6.7

3.4

1370

6.76

39

1

1

1

1

1

64

Alcohol

55

6.9

7.2

1362

7.02

48

1

1

1

2

1

65

Control

55

6.7

8.3

1631

6.39

12

0

0

1

9

0

66

Control

47

6.5

3.1

1534

6.74

38

0

0

1

1

1

68

Control

50

6.7

7.4

1426

6.37

30

1

0

0

0

1

69

Control

55

6.3

4.4

1560

6.89

39

0

0

1

2

0

70

Alcohol

53

5.8

5

1340

6.75

57

1

1

1

9

1

73

Control

82

5.3

3.4

1300

6.24

36

0

0

9

9

0

74

Control

64

6.5

7.8

1390

6.94

9.5

1

1

1

9

1

76

Alcohol

73

6.8

8

1188

6.84

19

1

0

1

9

1

77

Control

73

6

3.2

1380

6.8

48

1

0

9

9

1

80

Control

57

7.7

3.1

1360

6.6

18

0

0

1

9

2

82

Control

59

5.3

3.6

1360

6.56

20

1

0

0

9

1

*Please refer to Table 2 for dummy code reference for hemisphere, neuropathology (Neuro.), hepatology
(Hepat.), Toxicology (Tox.), and smoking
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Appendix II: Supplemental Methodology
AUD GWAS Enrichment:
To compare the overlap between our eQTL results with GWAS of other addiction phenotypes,
such as for alcohol use and smoking. We began by first isolating all SNPs in LD (r2= 0.50) using the data
available from the 1000 Genomes Project. We used Plink 1.9 to tag SNPs from the 1000 Genomes Project
in LD (r2=0.5, -tag-kb=500kb) with significant SNPs from our eQTL analyses. Next, all SNPs from the
curated list and those extracted from 1000Genomes were checked against our genotypic dataset to ensure
that they are all present. The annotations for this expanded list of SNPs was extracted from dbSNP
(https://www.ncbi.nlm.nih.gov/snp/), which also included SNPs mapped on different dbSNP build. This
list of SNPs was compared to two different GWAS: i) GWAS & Sequencing Consortium of Alcohol and Nicotine
Use (GSCAN), ii) Psychiatric Genetics Consortium AUD GWAS (PGC-AUD) (**only study 2) and iii) Collaborative
Study on the Genetics of Alcoholism (COGA) (*only study 1). The enrichment analyses are based on two stages: i)
to build competitive enrichment tests, recompute p-values to adjust for background enrichment, ii) use the
adjusted p-values to build two enrichment statistics that are optimal in different parts of the parameter
space. First, we adjust the p-values for background enrichment by recomputing the p-values under the
realized non-centrality parameter of GWAS based !!" = # " (chi-square) statistics of each SNP, where Z is
the Z-score of a GWAS SNP. Noncentrality parameter is estimated by the method of moments, i.e. we
+++" − 1,0), where #
+++" is the mean squares of Z-scores of all measured SNPs in the
can estimate $%" = max (#
genome scan. Second, we use adjusted p-values of eQTL SNPs to compute i) a Cauchy combination test
for p-values [35] that is heuristically more powerful when there are numerous signals and ii) a Simes test
that is likely to be most powerful when there are a few significant signals. The two enrichment statistics
are likely to cover all scenarios of practical importance.

Replication in the GTEx Database:
We began by performing an independent eQTL analysis on the NAc and PFC from the entire
22,214 probeset and genome-wide SNP data while controlling for all available covariates using the
modelLinear command within the MatrixEQTL package (ver. 2.2) in R. Next, we isolated significant
eQTLs (at FDR ≤0.05) containing SNPs with available RS IDs (NAc=160,119, PFC=35,990) from our
sample. This list of eQTLs was then compared to the significant (FDR≤0.05) list of eQTLs in NAc and
PFC with available RS IDs and gene symbols (HGNC) (NAc=854,654, PFC=718,679) from GTEx. The
overlap significance was tested via a Fisher’s exact test (at p ≤0.05).
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Appendix III: Network Preservation Supplemental (Study 1).
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Appendix IV: mRNA and miRNA eQTL results (Study 1).
NAc mRNA
SNPs
rs76383282

PFC mRNA
Gene

Module Color
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p-value
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1.08E-05

0.04

1.02110738

rs80021659

hsa-miR-550b_st

1.81E-05

0.05

-33.865258

rs60442281

hsa-miR-483-3p_st

2.42E-05

0.07

-2.0281147

rs11630961

hsa-miR-1282_st

2.91E-05

0.08

1.87410058

rs144850295

hsa-miR-550b_st

3.35E-05

0.08

-2.0630924

rs187535367

hsa-miR-550b_st

3.58E-05

0.08

-2.0944421

rs72724253

hsa-miR-1282_st

4.06E-05

0.09

1.46214249
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Appendix V: CircRNA hub annotation, significance to AD, and MM (Study 2).
Hub circRNA annotations

AD significance

WGCNA results

Probe ID

circRNA

chr/strand

circRNA type

Host Gene

AD reg coef

Std. Error

p-value

Module

MM

ASCRP3005798

hsa_circRNA_104238

chr6/+

exonic

TIAM2

0.35443566

0.15202303

0.02688424

M1

0.94221766

ASCRP3013231

hsa_circRNA_407198

chr9/-

intronic

ROR2

0.51011825

0.21113002

0.02221041

M1

0.91358434

ASCRP3004776

hsa_circRNA_406791

chr6/+

exonic

ZNF451

0.47500323

0.21098971

0.03211394

M1

0.8980134

ASCRP3013402

hsa_circRNA_101064

chr12/-

exonic

TFCP2

0.52462988

0.20298153

0.0150484

M1

0.89673576

ASCRP3009617

hsa_circRNA_405609

chr17/+

intronic

VMP1

0.47675388

0.18909361

0.01744529

M1

0.889519

ASCRP3004153

hsa_circRNA_400947

chr12/-

exonic

HDAC7

0.24319989

0.0765922

0.00353466

M1

0.86470334

ASCRP3012052

hsa_circRNA_006578

chr1/-

exonic

STK40

0.33280078

0.15698306

0.04268664

M1

0.86089489

ASCRP3004438

hsa_circRNA_102088

chr17/-

exonic

HDAC5

0.24577477

0.09132429

0.01169246

M1

0.85797797

ASCRP3007815

hsa_circRNA_102724

chr2/-

exonic

FANCL

0.33739302

0.16136414

0.04541244

M1

0.85241129

ASCRP3013243

hsa_circRNA_405786

chr19/+

intronic

AXL

0.32509416

0.15257405

0.04171694

M1

0.8494327

ASCRP3011731

hsa_circRNA_001952

chr13/+

antisense

DACH1

0.38640241

0.17227296

0.03270802

M1

0.84934091

ASCRP3010143

hsa_circRNA_000928

chr19/+

exonic

PROSER3

0.21977097

0.10627248

0.04766341

M1

0.84290986

ASCRP3013224

hsa_circRNA_403649

chr6/+

exonic

DOPEY1

0.35270831

0.14253645

0.01943426

M1

0.84080607

ASCRP3004117

hsa_circRNA_406138

chr21/-

intergenic

0.29684996

0.11587426

0.01587307

M1

0.83638201

ASCRP3007019

hsa_circRNA_104716

chr8/-

exonic

TSNARE1

0.28114238

0.13437958

0.04529021

M1

0.82540135

ASCRP3011336

hsa_circRNA_404433

chr1/+

exonic

KIF1B

0.31274942

0.14586749

0.04054152

M1

0.82260889

ASCRP3004513

hsa_circRNA_001109

chr2/-

sense overlapping

AFF3

0.26592524

0.11326323

0.02591503

M1

0.81991794

ASCRP3000686

hsa_circRNA_003627

chr17/+

exonic

RPA1

0.25669147

0.11420871

0.03237938

M1

0.81226741

ASCRP3011402

hsa_circRNA_000599

chr15/+

exonic

USP8

0.31723606

0.12878351

0.01994012

M1

0.80963714

ASCRP3012636

hsa_circRNA_402355

chr2/+

exonic

PTPN4

0.30953303

0.13940707

0.03436812

M1

0.80469802

ASCRP3003348

hsa_circRNA_101553

chr15/+

exonic

SNX1

0.45883161

0.21321919

0.03986267

M1

0.80302553

ASCRP3007718

hsa_circRNA_102066

chr17/+

exonic

CASC3

0.31495929

0.11000405

0.00771369

M1

0.80008902

ASCRP3000614

hsa_circRNA_066970

chr3/+

exonic

EAF2

0.35817045

0.13066026

0.01037176

M1

0.79926977

ASCRP3000325

hsa_circRNA_004145

chr5/-

sense overlapping

SKP1

0.27202296

0.1304037

0.04588373

M1

0.79923311

ASCRP3013140

hsa_circRNA_103131

chr21/-

exonic

BRWD1

0.33956506

0.15413413

0.0356893

M1

0.78504495

ASCRP3003195

hsa_circRNA_405845

chr2/+

exonic

CLIP4

0.32494803

0.12032928

0.01143664

M1

0.78271929

ASCRP3003221

hsa_circRNA_401450

chr15/+

exonic

GLCE

0.32306621

0.15614008

0.04755458

M1

0.78212412

ASCRP3003233

hsa_circRNA_068109

chr3/+

exonic

USP13

0.29547096

0.11394707

0.01475335

M1

0.77989862

ASCRP3001294

hsa_circRNA_002863

chr2/-

exonic

GFPT1

0.27170284

0.1121201

0.02185009

M1

0.77376144

ASCRP3011074

hsa_circRNA_100947

chr11/+

exonic

CUL5

0.24034022

0.07330821

0.0027133

M1

0.76727912

ASCRP3011384

hsa_circRNA_400057

chr2/+

intronic

RNU6-81P

0.28378008

0.13538257

0.04490908

M1

0.76330876
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ASCRP3012980

hsa_circRNA_072473

chr5/+

exonic

SKIV2L2

0.43550153

0.20492988

0.04222006

M1

0.75602247

ASCRP3009543

hsa_circRNA_100927

chr11/-

ASCRP3003793

hsa_circRNA_083996

chr8/-

exonic

PICALM

0.21553433

0.07223817

0.00572776

M1

0.75547759

exonic

WHSC1L1

0.34778166

0.14139635

0.02011035

M1

ASCRP3007240

hsa_circRNA_072837

0.75027107

chr5/-

exonic

SMA5

0.3381052

0.14328295

0.02523416

M1

ASCRP3003607

0.74487048

hsa_circRNA_100472

chr1/+

exonic

SNAP47

0.22009696

0.0798228

0.00997751

M1

0.74479474

ASCRP3011338

hsa_circRNA_001206

chr22/+

exonic

CRKL

0.23732784

0.10282578

0.02832513

M1

0.74287095

ASCRP3002395

hsa_circRNA_104346

chr7/-

exonic

HERPUD2

0.36667831

0.1741731

0.0440474

M1

0.74254149

ASCRP3004033

hsa_circRNA_074217

chr5/-

exonic

ECSCR

0.18179942

0.07666611

0.02458294

M1

0.73873942

ASCRP3008271

hsa_circRNA_001869

chr9/-

exonic

ZCCHC6

0.30568469

0.10322203

0.00605333

M1

0.73857296

ASCRP3008173

hsa_circRNA_001382

chr15/-

sense overlapping

MYO5A

0.15322943

0.06816952

0.03236475

M1

0.73567313

ASCRP3007831

hsa_circRNA_102594

chr19/+

exonic

POLD1

0.18923428

0.08632104

0.03653948

M1

0.73126997

ASCRP3004112

hsa_circRNA_102593

chr19/+

exonic

POLD1

0.18983574

0.08494774

0.03330372

M1

0.72239186

ASCRP3005188

hsa_circRNA_100485

chr1/-

exonic

PCNXL2

0.21126124

0.10075211

0.04484169

M1

0.71499591

ASCRP3002658

hsa_circRNA_405472

chr16/+

exonic

RP11-467L24.1

0.23021737

0.09189787

0.01810873

M1

0.70957154

ASCRP3004770

hsa_circRNA_028241

chr12/-

exonic

ATXN2

0.33169726

0.16107141

0.04854237

M1

0.70881893

ASCRP3011126

hsa_circRNA_020515

chr10/-

exonic

TCERG1L

0.16891327

0.07753227

0.03763208

M1

0.70566561

ASCRP3010987

hsa_circRNA_008338

chr11/+

exonic

ZNF215

0.26646012

0.0882357

0.0052329

M2

0.87469856

ASCRP3003317

hsa_circRNA_016266

chr1/+

exonic

MAPKAPK2

0.3087154

0.12956967

0.02396353

M2

0.86188897

ASCRP3007546

hsa_circRNA_404836

chr11/-

intronic

NUP98

0.27121256

0.10522022

0.01529909

M2

0.85328554

ASCRP3011725

hsa_circRNA_104602

chr8/-

exonic

SLC20A2

0.1827308

0.08597594

0.0421978

M2

0.84535449

ASCRP3003107

hsa_circRNA_012173

chr1/+

exonic

RPS8

0.247996

0.11581063

0.04077473

M2

0.82605393

ASCRP3000643

hsa_circRNA_103700

chr4/+

exonic

HERC5

0.29145241

0.1289739

0.03152095

M2

0.82575969

ASCRP3012923

hsa_circRNA_056204

chr2/+

exonic

DDX18

0.26747828

0.08419095

0.0035186

M2

0.80364145

ASCRP3012903

hsa_circRNA_014234

chr1/-

exonic

S100A2

0.36336494

0.1748495

0.04665184

M2

0.76206174

ASCRP3005732

hsa_circRNA_001645

chr6/+

exonic

HECA

0.2351102

0.11091365

0.0427067

M2

0.75368353

ASCRP3010524

hsa_circRNA_000484

chr13/-

sense overlapping

RCBTB1

0.26922141

0.11083312

0.02156563

M2

0.73010011

ASCRP3012482

hsa_circRNA_025614

chr12/-

exonic

C2CD5

0.25960913

0.12268139

0.04303911

M2

0.72383444

ASCRP3001284

hsa_circRNA_406606

chr5/-

intronic

PDE4D

0.32490049

0.11534296

0.00863787

M2

0.71649793

ASCRP3011980

hsa_circRNA_405066

chr12/+

exonic

IFT81

0.20244031

0.08546224

0.02472435

M2

0.71466666

ASCRP3009946

hsa_circRNA_027691

chr12/+

exonic

TMTC3

0.28021105

0.11361564

0.01980422

M2

0.71443406

ASCRP3010884

hsa_circRNA_103569

chr3/+

exonic

LRCH3

0.22469484

0.09609202

0.0264741

M2

0.70186442

ASCRP3002957

hsa_circRNA_079387

chr7/+

exonic

C7orf26

0.18339509

0.07695239

0.02393067

M2

0.70178121

ASCRP3005003

hsa_circRNA_082089

chr7/-

exonic

POT1

0.21909642

0.09448697

0.02765523

M4

0.85868089

ASCRP3012301

hsa_circRNA_027451

chr12/-

exonic

GRIP1

0.19712131

0.08745133

0.03191965

M4

0.84205529

ASCRP3002168

hsa_circRNA_005843

chr2/-

sense overlapping

LINC01473

0.28006767

0.13359323

0.04488176

M4

0.82654505

ASCRP3010761

hsa_circRNA_002663

chr8/-

exonic

C8orf76

0.23763198

0.10557362

0.03214536

M4

0.7810837
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ASCRP3005182

hsa_circRNA_100518

chr10/+

exonic

ZMYND11

0.20822005

0.08938427

0.02700275

M4

0.74731456

ASCRP3013237

hsa_circRNA_001785

chr10/+

sense overlapping

FAM208B

0.21924285

0.09867358

0.03425222

M4

0.720688

ASCRP3008151

hsa_circRNA_102203

chr17/+

exonic

SNHG20

0.17587906

0.07303328

0.02261427

M4

0.7194125

ASCRP3001569

hsa_circRNA_405886

chr2/+

exonic

PAPOLG

0.24799651

0.09710863

0.01617321

M4

0.71665054

ASCRP3008631

hsa_circRNA_400623

chr10/-

exonic

TLL2

0.28116629

0.10664684

0.01331936

M4

0.70848352

ASCRP3011641

hsa_circRNA_007290

chrX/-

sense overlapping

FUNDC1

0.23985978

0.10098358

0.02436647

M4

0.70504507

ASCRP3002274

hsa_circRNA_101342

chr14/-

exonic

SNX6

0.3750327

0.1760794

0.04179052

M5

0.87819052

ASCRP3012325

hsa_circRNA_000390

chr4/-

sense overlapping

PDS5A

0.23350004

0.10307318

0.03113406

M5

0.85683567

ASCRP3000049

hsa_circRNA_101915

chr16/-

exonic

FANCA

0.26286608

0.09422644

0.00922543

M5

0.82846255

ASCRP3004492

hsa_circRNA_104016

chr5/+

exonic

ERGIC1

0.23365789

0.10908668

0.04072624

M5

0.81875582

ASCRP3004943

hsa_circRNA_406001

chr2/+

sense overlapping

LOC101927156

0.22841652

0.10933782

0.04558504

M5

0.81835246

ASCRP3007335

hsa_circRNA_003223

chr15/-

exonic

MYO1E

0.20478554

0.08174458

0.01810687

M5

0.81575422

ASCRP3010857

hsa_circRNA_090302

chrX/-

exonic

CASK

0.28936389

0.11771578

0.02017805

M5

0.81411439

ASCRP3001147

hsa_circRNA_404886

chr11/+

exonic

PTPRJ

0.24349849

0.11594432

0.04452938

M5

0.80784965

ASCRP3001645

hsa_circRNA_100282

chr1/-

exonic

DNTTIP2

0.33144138

0.12683521

0.01407145

M5

0.79334849

ASCRP3007290

hsa_circRNA_402705

chr22/+

exonic

SPECC1L

0.2900758

0.12107844

0.02326126

M5

0.79297793

ASCRP3002043

hsa_circRNA_101896

chr16/-

exonic

ZCCHC14

0.26899917

0.12631672

0.04182144

M5

0.77642946

ASCRP3001686

hsa_circRNA_001675

chr7/+

sense overlapping

C1GALT1

0.2565116

0.09974028

0.01550739

M5

0.77247558

ASCRP3002969

hsa_circRNA_001219

chr22/+

exonic

MTMR3

0.17693847

0.05871006

0.00531333

M5

0.75744423

ASCRP3004769

hsa_circRNA_104802

chr9/-

exonic

TLE1

0.26060294

0.10879576

0.02328375

M5

0.74707673

ASCRP3003876

hsa_circRNA_014522

chr1/-

exonic

CLK2

0.19247331

0.07216819

0.01238715

M5

0.74488554

ASCRP3004186

hsa_circRNA_092390

chr11/+

exonic

PPP6R3

0.23025699

0.0932106

0.01962396

M5

0.73505363

ASCRP3007763

hsa_circRNA_104151

chr6/-

exonic

TBX18

0.24025492

0.09974064

0.02258386

M5

0.73249948

ASCRP3001614

hsa_circRNA_104196

chr6/-

exonic

MAP3K5

0.18255205

0.08778773

0.04652256

M5

0.72922586

ASCRP3012567

hsa_circRNA_102678

chr2/+

exonic

CRIM1

0.2008596

0.09448068

0.04214718

M5

0.71271344

ASCRP3001973

hsa_circRNA_403425

chr5/+

exonic

PHAX

0.27359069

0.09523639

0.0075344

M5

0.70554058

ASCRP3002010

hsa_circRNA_402803

chr3/+

exonic

NR1D2

-0.8089296

0.3519938

0.02895689

M6

0.89469405

ASCRP3006813

hsa_circRNA_103457

chr3/-

exonic

TPRA1

-0.6084868

0.25630949

0.02443274

M6

0.88836295

ASCRP3005036

hsa_circRNA_001257

chr22/-

sense overlapping

PLXNB2

-0.4821966

0.23570514

0.04994422

M6

0.85630389

ASCRP3002336

hsa_circRNA_104040

chr6/+

exonic

DUSP22

-0.6353853

0.24521556

0.0148202

M6

0.8558968

ASCRP3000892

hsa_circRNA_003615

chr11/-

exonic

ALG8

-0.4594455

0.21269272

0.03916414

M6

0.85376399

ASCRP3002575

hsa_circRNA_000480

chr13/+

antisense

ZC3H13

-0.5545388

0.23581789

0.02570047

M6

0.82927864

ASCRP3002992

hsa_circRNA_103561

chr3/+

exonic

SENP5

-0.6137306

0.26457498

0.02760072

M6

0.82697052

ASCRP3012503

hsa_circRNA_005279

chr12/+

exonic

ATP2A2

-0.7007767

0.29665507

0.02508935

M6

0.81984686

ASCRP3011050

hsa_circRNA_004121

chr2/-

exonic

RFX8

-0.5300998

0.23895363

0.03451346

M6

0.81747132

ASCRP3007931

hsa_circRNA_024326

chr11/+

exonic

NNMT

-0.2846048

0.10518118

0.01129087

M6

0.80747642
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ASCRP3013054

hsa_circRNA_104942

chr9/+

exonic

ASCRP3000768

hsa_circRNA_043366

chr17/+

exonic

ASCRP3007811

hsa_circRNA_000551

chr14/-

exonic

ASCRP3005461

hsa_circRNA_037886

chr16/-

exonic

ASCRP3011978

hsa_circRNA_000298

chr11/-

exonic

ASCRP3009290

hsa_circRNA_000178

chr14/+

ASCRP3009271

hsa_circRNA_104969

chr9/+

ASCRP3005489

hsa_circRNA_085362

ASCRP3005132

NUP214

-0.5009155

0.16125614

0.00421025

M6

0.80587128

PSMB3

-0.339962

0.15537483

0.03687418

M6

0.77922278

SLC8A3

-0.3293925

0.15261367

0.03931591

M6

0.7698561

ZC3H7A

-0.4087057

0.17751235

0.0286834

M6

0.75301779

ARFGAP2

-0.2581876

0.10747347

0.02291737

M6

0.74057624

intronic

SRSF5

-0.4708265

0.18557467

0.01681395

M6

0.73325107

exonic

EHMT1

-0.28011

0.12479745

0.03259686

M6

0.73321926

chr8/-

exonic

TRPS1

-0.2673359

0.10483961

0.01631924

M6

0.72561762

hsa_circRNA_101134

chr12/+

exonic

UNG

-0.2699215

0.09665287

0.00915941

M7

0.86906736

ASCRP3001917

hsa_circRNA_405170

chr13/-

exonic

UGGT2

-0.3121867

0.11024324

0.00832833

M7

0.85433648

ASCRP3010045

hsa_circRNA_001328

chr3/+

exonic

SIDT1

-0.4459471

0.09098788

3.34E-05

M7

0.78502413

ASCRP3004191

hsa_circRNA_104431

chr7/-

exonic

SMURF1

-0.2332906

0.10207365

0.0297791

M7

0.77120202

ASCRP3000591

hsa_circRNA_102823

chr2/+

exonic

RAB3GAP1

-0.189554

0.08682197

0.03725675

M7

0.76565465

ASCRP3005878

hsa_circRNA_104787

chr9/-

exonic

PTAR1

-0.2388903

0.0965745

0.01947344

M7

0.76474987

ASCRP3002334

hsa_circRNA_092505

chr20/-

intronic

CPNE1

-0.2037535

0.09868391

0.0479947

M7

0.75894305

ASCRP3011575

hsa_circRNA_406742

chr6/-

exonic

KIF13A

-0.2331309

0.10826225

0.03973722

M7

0.72461502

ASCRP3011450

hsa_circRNA_075013

chr5/+

exonic

NPM1

-0.2946804

0.083129

0.00135461

M7

0.71937225

ASCRP3008301

hsa_circRNA_080252

chr7/+

exonic

GBAS

-0.1964349

0.07829959

0.01795784

M8

0.83192628

ASCRP3000788

hsa_circRNA_010991

chr1/+

exonic

LIN28A

-0.1897628

0.07755901

0.02071501

M8

0.74076731

ASCRP3008149

hsa_circRNA_405785

chr19/-

intronic

ADCK4

-0.2340716

0.0845337

0.00970067

M8

0.73997002

ASCRP3004702

hsa_circRNA_015279

chr1/+

exonic

KLHL20

-0.1977976

0.0519646

0.00067499

M8

0.72696137

ASCRP3013378

hsa_circRNA_065645

chr3/-

exonic

RHOA

-0.1889056

0.09228419

0.04981486

M8

0.72266809

ASCRP3000523

hsa_circRNA_005585

chr5/+

sense overlapping

NNT

-0.2202702

0.07746897

0.00809707

M9

0.815283

ASCRP3005981

hsa_circRNA_006205

chr4/+

sense overlapping

C4orf22

-0.3040979

0.10715352

0.00820396

M9

0.79427612

ASCRP3005437

hsa_circRNA_100345

chr1/-

exonic

C1orf43

-0.2204489

0.10448191

0.04361161

M9

0.77182837

ASCRP3011470

hsa_circRNA_102251

chr17/+

exonic

TBCD

-0.2633029

0.10505837

0.01806229

M9

0.7624032

ASCRP3002486

hsa_circRNA_404845

chr11/+

exonic

IPO7

-0.2945553

0.12814287

0.02892398

M9

0.74069027

ASCRP3009183

hsa_circRNA_001826

chr21/+

exonic

DYRK1A

-0.2377539

0.09009638

0.01324203

M9

0.71568113

ASCRP3000168

hsa_circRNA_102324

chr18/-

exonic

TMEM241

-0.5177016

0.22791147

0.03071624

M10

0.80024805

ASCRP3000042

hsa_circRNA_000566

chr14/+

exonic

VRK1

-0.2577258

0.08214161

0.00388996

M10

0.77712929

ASCRP3007631

hsa_circRNA_003792

chr12/+

exonic

CACNA1C

-0.2254746

0.1049032

0.04008319

M10

0.76047186

ASCRP3013458

hsa_circRNA_104538

chr7/-

exonic

LMBR1

-0.2980633

0.09882928

0.00528452

M10

0.74089866

ASCRP3006716

hsa_circRNA_102920

chr2/-

exonic

ABCB6

-0.3354041

0.15465548

0.03844602

M10

0.73522876

ASCRP3010153

hsa_circRNA_001072

chr16/+

sense overlapping

TSC2

-0.2479528

0.11265409

0.03584794

M10

0.72544641
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Appendix VI: Regression results for circRNA x miRNA interaction effect
on mRNA expression (Study 2).
circRNA

miRNA

mRNA

Estimate

Std. Error

t-value

p-value

FDR

ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3005132
ASCRP3011575
ASCRP3010153
ASCRP3011575
ASCRP3013378
ASCRP3001917
ASCRP3011575
ASCRP3012325
ASCRP3011575
ASCRP3011575
ASCRP3011575
ASCRP3012301
ASCRP3005878
ASCRP3010524
ASCRP3011575
ASCRP3001645
ASCRP3002043
ASCRP3012325
ASCRP3013378
ASCRP3011575
ASCRP3011575
ASCRP3012325
ASCRP3012325
ASCRP3011575
ASCRP3012325
ASCRP3001686
ASCRP3012325
ASCRP3000049
ASCRP3000049
ASCRP3001645
ASCRP3012325
ASCRP3013054
ASCRP3012325
ASCRP3013054

hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-1200
hsa-miR-665
hsa-miR-1200
hsa-miR-3187-3p
hsa-miR-1200
hsa-miR-571
hsa-miR-4310
hsa-miR-1200
hsa-miR-361-5p
hsa-miR-1200
hsa-miR-498
hsa-miR-1200
hsa-miR-361-5p
hsa-miR-1207-5p
hsa-miR-3119
hsa-miR-1200
hsa-miR-646
hsa-miR-378c
hsa-miR-361-5p
hsa-miR-571
hsa-miR-1200
hsa-miR-498
hsa-miR-361-5p
hsa-miR-361-5p
hsa-miR-1200
hsa-miR-361-5p
hsa-miR-4760-3p
hsa-miR-361-5p
hsa-miR-4762-5p
hsa-miR-4762-5p
hsa-miR-646
hsa-miR-361-5p
hsa-miR-3652
hsa-miR-361-5p
hsa-miR-193a-3p

IMP4
SSX2IP
PRKCB
ASTN1
PCLO
HOMER1
OSBPL8
ATP2B2
HRAS
IPCEF1
LDB2
NDST3
RAB11FIP2
MLEC
RANBP2
GPD2
RFC2
NR3C1
CELF1
ACTR2
NEK7
E2F3
RBFOX1
PDP1
RALBP1
MLEC
MYOF
GPC5
ANP32B
SEC31A
NDE1
NRP2
KDM5B
ATP2B1
FGF1
SEC62
ZNF106
MBOAT2
NEK7
ZEB2
LSM14A
sec24a
PAIP2B
SMARCC1
LAMC2
FRYL
LAMC2

1.53054528
2.02378019
5.35165333
2.06198402
2.560338
1.78678466
1.91611762
2.58793864
1.82606095
2.09463746
3.51554896
2.73526849
0.90610204
-0.6226648
0.8802594
-0.7689576
0.83560553
-1.5578533
0.6516508
0.81274224
2.25849437
0.90432912
1.02469005
1.16762774
-0.6320372
-0.3025057
-2.7366467
0.72909057
1.64097282
0.47802494
-1.6410513
-0.071787
0.61064174
0.66194684
1.07676919
0.32745852
0.25997019
-0.6832299
1.6031339
-0.6890341
-0.3283677
-0.3687521
0.46946142
-0.1782521
0.07744802
-0.1311396
0.03529401

0.28882896
0.42024329
1.08293375
0.52687919
0.66692909
0.48749802
0.53436057
0.72495034
0.49999695
0.60716557
1.01237131
0.81163132
0.27438872
0.1964143
0.32381172
0.29016294
0.31447229
0.6327597
0.29988509
0.36931016
1.0432361
0.42352137
0.53820813
0.76221328
0.41954121
0.24227865
2.16538406
0.59197619
1.40199918
0.4152337
1.4809833
0.0664586
0.60528983
0.66172879
1.11904466
0.36698391
0.32441278
0.85140254
2.98776095
1.343039
0.68567705
0.93827517
2.36500614
0.80878717
0.42711806
0.88015382
0.43576684

5.29914066
4.81573468
4.94181048
3.91358031
3.83899586
3.66521419
3.58581399
3.56981504
3.65214416
3.44986206
3.47258849
3.37008742
3.30225692
-3.17016
2.71842972
-2.6500891
2.65716745
-2.4619983
2.17300165
2.20070369
2.16489284
2.1352621
1.90389181
1.53189109
-1.5064962
-1.248586
-1.2638159
1.23162145
1.17045205
1.15121902
-1.1080823
-1.0801763
1.0088419
1.0003295
0.96222183
0.89229668
0.80135621
-0.8024758
0.53656699
-0.513041
-0.4788956
-0.3930106
0.19850326
-0.2203943
0.18132697
-0.1489962
0.08099288

1.72E-05
6.01E-05
4.33E-05
0.00061837
0.00074829
0.00116416
0.00142282
0.00148135
0.00120332
0.00200163
0.00189102
0.00244195
0.00288906
0.00399749
0.01174565
0.01375386
0.01353182
0.02106023
0.03946215
0.03721356
0.04014311
0.04272217
0.06849601
0.13810705
0.1444724
0.22338302
0.21795402
0.22955048
0.25285592
0.26053392
0.27837347
0.29037466
0.32271566
0.32673562
0.3451535
0.38074255
0.43047653
0.42984081
0.59630978
0.61242664
0.63617506
0.697643
0.84425677
0.82735396
0.85757305
0.88275205
0.93609254

0.00080937
0.00094102
0.00094102
0.00703394
0.00703394
0.00773595
0.00773595
0.00773595
0.00773595
0.00855244
0.00855244
0.00956431
0.01044506
0.01342016
0.03680303
0.03802538
0.03802538
0.05499059
0.0898441
0.0898441
0.0898441
0.0912701
0.13997012
0.27045965
0.27160811
0.38531688
0.38531688
0.38531688
0.40816981
0.40816981
0.42205011
0.42648778
0.45166394
0.45166394
0.46349185
0.49708056
0.53243149
0.53243149
0.71862974
0.7196013
0.72927385
0.78069574
0.8956874
0.8956874
0.8956874
0.90194231
0.93609254
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Appendix VII: CircRNA linear and SNP x AD interaction eQTL results (Study 2).
Linear eQTL
statistic
pvalue

0

snps

Linear cross eQTL (SNP x AD interaction)
circRNA
statistic
pvalue

snps

gene

FDR

beta

FDR

beta

rs7991424

ASCRP3002575

-6.4839202

5.97E-07

0.02017828

-2.1202211

rs118155171

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs61811887

ASCRP3012903

6.15129134

1.42E-06

0.02017828

1.93779544

rs147144673

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs147100105

ASCRP3012903

6.15129134

1.42E-06

0.02017828

1.93779544

rs148170759

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs117006970

ASCRP3005461

4.95184011

3.47E-05

0.30222579

2.56672245

rs180683570

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs4720180

ASCRP3002395

-4.8940485

4.05E-05

0.30222579

-0.4388986

rs151187972

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs184047156

ASCRP3005461

4.87532064

4.26E-05

0.30222579

2.54766753

rs140694617

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs149248212

ASCRP3009183

4.50201216

0.00011606

0.69824913

0.75503628

rs138568769

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs11062213

ASCRP3007631

4.44041383

0.00013689

0.69824913

0.4513061

rs77334228

ASCRP3008301

5.23348349

1.82E-05

0.09670093

0.19908219

rs56322298

ASCRP3002395

4.38946477

0.0001569

0.69824913

0.56086768

rs61827881

ASCRP3004702

5.05996029

2.87E-05

0.13575513

0.05710754

rs1468762

ASCRP3001686

4.34981277

0.00017446

0.69824913

0.27292089

rs2239015

ASCRP3007631

5.01930513

3.19E-05

0.13600717

0.11917738

rs947505

ASCRP3004702

-4.3373903

0.00018035

0.69824913

-0.3228061

chr12:2536700:I

ASCRP3007631

4.86756087

4.77E-05

0.1750147

0.14313142

chr6:139272248:I

ASCRP3005732

-4.2288632

0.00024097

0.75844579

-0.7539022

rs4948043

ASCRP3008301

4.85468939

4.93E-05

0.1750147

0.09318458

rs12492090

ASCRP3002010

-4.1931115

0.00026505

0.75844579

-0.8207713

rs4277019

ASCRP3011126

4.77215527

6.13E-05

0.20089723

1.13301319

rs112113277

ASCRP3003195

-4.1602198

0.00028931

0.75844579

-0.7319037

rs4298454

ASCRP3008301

-4.5847017

0.0001006

0.30603124

-0.1422843

rs181041915

ASCRP3004702

4.14744353

0.00029931

0.75844579

0.73089863

rs7963869

ASCRP3007631

-4.4785861

0.00013311

0.35151965

-2.725036

rs8049561

ASCRP3010153

4.11096678

0.00032978

0.75844579

0.77531915

rs10798295

ASCRP3004702

4.47772271

0.00013341

0.35151965

0.05109809

rs954178

ASCRP3011450

4.0978199

0.0003415

0.75844579

1.06320788

rs6578758

ASCRP3010987

4.45857696

0.00014032

0.35151965

0.17966129

rs147614021

ASCRP3004702

4.05030527

0.00038737

0.75844579

0.71265141

rs10774039

ASCRP3007631

4.40257344

0.00016264

0.35264922

0.14252394

rs7950251

ASCRP3010987

4.0328892

0.00040567

0.75844579

0.73048309

rs143831739

ASCRP3008301

4.39808668

0.00016457

0.35264922

4.50745552

rs61826691

ASCRP3004702

4.03147097

0.0004072

0.75844579

0.71099519

rs35065145

ASCRP3004702

4.39568866

0.00016561

0.35264922

0.08337201

rs192039723

ASCRP3004769

-4.0068284

0.00043465

0.75844579

-1.1806904

rs6681720

ASCRP3004702

-4.2981748

0.00021407

0.4295439

-0.0953619

rs77368889

ASCRP3004769

-4.0068284

0.00043465

0.75844579

-1.1806904

rs2227596

ASCRP3004702

4.27334915

0.00022851

0.4295439

0.08476655

rs11119030

ASCRP3003317

3.99304799

0.00045078

0.75844579

0.31167284

rs1951625

ASCRP3004702

4.21947637

0.00026324

0.4295439

0.08141193

rs114699482

ASCRP3012567

3.96767968

0.00048204

0.75844579

0.43657578

rs6425224

ASCRP3004702

-4.1624815

0.00030569

0.4295439

-0.0808469

rs191164384

ASCRP3011450

3.94298456

0.00051452

0.75844579

1.03832699

chr16:11993187:I

ASCRP3005461

-4.1576308

0.0003096

0.4295439

-2.5465823

rs77560264

ASCRP3011126

-3.9264141

0.00053751

0.75844579

-0.8575376

chr1:173429147:I

ASCRP3004702

4.15048838

0.00031545

0.4295439

0.09916557

rs74086799

ASCRP3000042

3.91324874

0.00055649

0.75844579

0.36590434

rs2208849

ASCRP3004702

4.14770559

0.00031776

0.4295439

0.07350117

rs7001536

ASCRP3010761

3.89703036

0.00058079

0.75844579

0.2986662

rs56037160

ASCRP3007335

-4.1446

0.00032035

0.4295439

-0.9807878

rs7130042

ASCRP3010987

3.887231

0.00059597

0.75844579

0.26369392

rs2283294

ASCRP3007631

-4.1296951

0.00033311

0.4295439

-0.0800983

rs6584077

ASCRP3008631

3.8530278

0.00065206

0.75844579

0.3316877

rs7811548

ASCRP3008301

4.10663718

0.00035383

0.4295439

0.14872392
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rs140398314

ASCRP3013224

-3.8507165

0.00065603

0.75844579

-1.6663334

rs2695582

ASCRP3013458

-4.103989

0.00035629

0.4295439

-0.1448899

rs111500971

ASCRP3013224

-3.8507165

0.00065603

0.75844579

-1.6663334

rs4948042

ASCRP3008301

4.10016327

0.00035988

0.4295439

0.07381557

rs11755735

ASCRP3001614

3.84337588

0.00066881

0.75844579

0.65991286

rs6661868

ASCRP3004702

4.09888203

0.00036109

0.4295439

0.08007398

rs75023617

ASCRP3008173

-3.8405946

0.00067371

0.75844579

-0.5460872

chr8:116515360:I

ASCRP3005489

-4.0924627

0.0003672

0.4295439

-1.4690301

rs112653441

ASCRP3002992

-3.8196149

0.00071185

0.75844579

-1.390168

rs1951627

ASCRP3004702

4.05645952

0.00040344

0.4295439

0.07868624

rs144961584

ASCRP3008301

3.80412425

0.00074136

0.75844579

1.01078695

chr6:83982034:I

ASCRP3013224

-4.0563507

0.00040356

0.4295439

-0.2389517

rs72909043

ASCRP3010987

3.79809872

0.00075316

0.75844579

0.70590666

rs618513

ASCRP3009543

-4.0349897

0.00042671

0.4295439

-0.7957842

rs6915606

ASCRP3002336

-3.7895017

0.00077032

0.75844579

-0.8312831

rs16845720

ASCRP3004702

4.01639695

0.00044793

0.4295439

0.09222312

rs13327482

ASCRP3002992

-3.7871545

0.00077507

0.75844579

-0.9003206

chr1:173832772:I

ASCRP3004702

4.00805274

0.00045779

0.4295439

0.07746833

chr3:196876775:I

ASCRP3002992

-3.7871545

0.00077507

0.75844579

-0.9003206

rs142085364

ASCRP3006716

4.00793637

0.00045793

0.4295439

0.31175239

rs3889250

ASCRP3002992

-3.7835403

0.00078244

0.75844579

-1.4146461

rs72711419

ASCRP3004702

4.00624618

0.00045995

0.4295439

0.09136714

rs185016961

ASCRP3002992

-3.7756558

0.00079875

0.75844579

-2.0498858

rs74348266

ASCRP3004702

4.00569976

0.00046061

0.4295439

0.09799906

rs61811927

ASCRP3012903

3.77068586

0.00080921

0.75844579

1.24171491

rs78972925

ASCRP3004702

3.99192899

0.00047745

0.4295439

0.09755645

rs62014212

ASCRP3003348

-3.7547925

0.00084356

0.75844579

-1.4667056

rs114032493

ASCRP3004702

3.99192899

0.00047745

0.4295439

0.09755645

rs118053682

ASCRP3003348

-3.7547925

0.00084356

0.75844579

-1.4667056

rs34672369

ASCRP3008301

3.9696333

0.00050601

0.4295439

0.0761465

rs76154462

ASCRP3009543

-3.7531916

0.00084709

0.75844579

-0.7368734

rs590401

ASCRP3009543

3.96937047

0.00050635

0.4295439

0.85621318

rs131800

ASCRP3005036

3.74061068

0.0008754

0.75844579

1.82692568
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